Investigation of the potential molecular recognition sites of two human vitamin C transporters. by Domeneghetti, Camilla
 Faculty of Science and Technology  
 
Investigation of the potential molecular recognition sites 
of two human vitamin C transporters. 
Site specific mutagenesis to modify certain codons of the coding 
genes. 
 
 
 
A thesis submitted as part of the requirement for the 
Masters of Research 
 
Camilla Freda Domeneghetti 
July 2018 
2 
 
This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and due 
acknowledgement must always be made of the use of any material contained in, or 
derived from, this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Acknowledgements 
I would like to thank my supervisor, Dr Wei-Jun Liang, for his continuous support, 
guidance and inspiration to this research. I would also like to thank my family and 
friends for their endless encouragement. Finally, I would like to give recognition to my 
fellow masters of research student, Christine who has reassured and helped me 
throughout this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Abstract 
Vitamin C (L-ascorbic acid), a cofactor for numerous mammalian enzymes and a well-
known antioxidant, is renowned for its range of health advantages and protective 
capabilities against degenerative disorders. The mechanisms regulating the cellular 
movement of ascorbic acid signify a primary aspect for recognising the roles played by 
vitamin C in human biology. The ability for this nutrient to be absorbed and occupied in 
cells is accomplished via the two sodium-coupled proteins, hSVCT1 and hSVCT2. The 
two transporters have varying roles in relation to ascorbate, nevertheless they are both 
rely on certain membrane targeting to achieve their essential functions. If the correct 
localisation for the two proteins is not found they are unable to complete their functions, 
leading to reduced transport capabilities. Deficiency of vitamin C in humans is fatal and 
has been linked with an increased chance of cancer and other degenerative diseases, 
therefore the two protein carriers are crucial for human health. Despite numerous 
studies evaluating vitamin C’s benefits for humans, detailed knowledge on the 
membrane targeting of the two transporters is still limited. It is unclear how these 
proteins react to the interaction and presence of new substances entering the human 
body and how this will affect their functionality. Consequently, the aim of this research 
is to modify the potential molecular recognition sites on the hSVCT1 and hSVCT2 
genes through site directed mutagenesis. This study could therefore indicate regions on 
the amino acid sequences which could be fundamental for functionality for the two 
carriers. This knowledge would assist the growth of therapeutic strategies in fighting 
certain conditions and even in the production of new drugs.   
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1.0 Introduction 
Vitamin C (L-ascorbic acid), is a crucial nutrient needed for human survival which is 
gained through the consumption of certain foods and dietary supplements. The 
micronutrient is acknowledged across the medical industry due to its involvement in 
numerous cellular reactions where it acts as a free radical scavenger by reducing the 
effects of oxidative stress. It is also notoriously known for its involvement in multiple 
degenerative disease, where it plays a protective role (Van der Reest and Gottlieb., 
2012).  Due to its water solubility, vitamin C needs specific protein carriers to enable it 
to move across plasma membranes. As humans do not naturally synthesise the nutrient 
these proteins are essential to enable absorption into cells, where it can complete its 
biological functions (Mun et al., 2006). The two human Na+- dependent vitamin C 
transporters, hSVCT1 and hSVCT2, are recognised to be accountable for the majority 
of cellular uptake of the nutrient in humans (Gess et al., 2005). It is evident that the 
human body therefore relies on only two transporters for survival which could seem 
unstable, particularly when minimal detailed knowledge is understood on their 
structural and functional influences. Throughout the pharmaceutical industry, new drugs 
and therapies are continually being developed to manage with the development of new 
diseases and disorders. It is therefore necessary to understand the potential for adverse 
drug reactions and how detect them within the human body. Understanding the 
mechanisms which control and shape a proteins behaviour and interactions with other 
substances, particularly in relation to vitamin C, is crucial. This knowledge could 
consequently aid our understanding on how vitamin C can be used as a treatment and 
preventive for a vast range of degenerative diseases linked with oxidative stress.  
        Therefore, this research project aims to complete site-specific mutagenesis on the 
two vitamin C transporters, hSVCT1 and hSVCT2 through molecular cloning 
techniques. These results can then provide fellow researchers with an insight into the 
molecular recognition sites of the transporters which are crucial for their functionality 
and biological activities. This could potentially lead to influencing how the 
pharmaceutical industry design and develop their medicines.  
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1.1 Vitamin C, Health and Disease  
Vitamin C (L-ascorbic acid, AA) is a fundamental micronutrient needed for normal 
cellular function and growth. The nutrient is chemically the simplest of the vitamins and 
consequently was one of the first to be characterised and have its structure determined. 
It is produced industrially more than any other vitamin and is taken routinely by human 
beings. The six-carbon lactone is produced from glucose in the liver in the majority of 
mammalian species, however not by humans, non-human primates and guinea pigs 
(Williams and Deason, 1967). Those mammals who can synthesise vitamin C do so via 
the L-gulono-y-lactone pathway (Burk et al., 2006). Humans have an inability to 
synthesise vitamin C due to mutations in the L-gulono-γ-lactone oxidase (GLO) gene, 
which codes for the final enzyme utilised in biosynthesis of the nutrient. Clinical 
expression of vitamin C deficiency, scurvy is a fatal disorder unless suitably treated, 
therefore humans are required to consume vitamin C to survive (Stone, 1966; McRae, 
2008). Symptoms of scurvy include fatigue, painful joints and muscles, fever and 
bleeding into the skin (Bsoul and Terezhalmy 2004; Montecinos et al. 2007).  
Studies into high levels of vitamin C in humans have suggested it has the ability to 
protect against certain conditions including cardiovascular disease, cataracts, cancer and 
Parkinson’s (Mahdavi et al. 2009; Ravindran et al. 2011; Bennett et al. 2012). The 
abilities that vitamin C holds in protecting against diseases and conditions routes from 
its function as a reducing agent, where it can donate an electron and convert to dehydro-
L-ascorbic acid (DHA) (Sagun et al., 2005; May 2011). The role of vitamin C in 
relation to human health has been researched for many years due to its numerous 
positive abilities and capability to work both inside and outside of cells. The most 
studied function of ascorbic acid is its primary role to neutralise free radicals due it is 
water soluble characteristics enabling it to inhibit large quantities of damage (Jelodar, 
Nazifi and Akbari, 2013). Vitamin C provides a beneficial source of electrons which are 
donated to the free radicals such as hydroxyl radicals (Klennel, 1949).  This action 
prevents the cells from being damaged by genetic alterations and prevents mutations to 
the chromosomes (Singh and Gaby, 1991).  
 Alongside the liver and adrenal glands the greatest levels of vitamin C in the body are 
found in the brain (140 mg/kg) and neuroendocrine tissue (Anderson et al., 1997). 
Inside the human body, vitamin C presents complex non-linear pharmacokinetics, in 
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addition to varying tissue distribution. This is also shown in the brain which is able to 
retain the vitamin at the deprivation of other tissues and organs, including the liver and 
kidney, during states of chronic deficiency (Lykkesfeldt et al., 2007). The brain is 
moderately resistant to vitamin C depletion, suggesting an essential role of the nutrient 
(Hejazi et al., 2011). AA acts has numerous functions within the brain including; 
monooxygenase-dependent synthesis of neurotransmitters and neuropeptide hormones, 
as well as recycling of the enzyme cofactor tetrahydrobiopterin (Lykkesfeldt et al., 
2007; Figueroa-Mendez and Rivas-Arancibia, 2015). The nutrient has also been proven 
to be involved in the physiology of the central nervous system and supporting the 
structure of particular neurons in addition to modulating the neurotransmission within 
human bodies (Flagg, Coates and Greenberg, 1995).  
Vitamin C levels have been linked to learning and memory with suggestions that 
combinations of vitamin C and E have advantageous effects reducing memory 
alterations (Arzi, Hemmati and Razian, 2004; Harrison et al., 2009). Studies conducted 
by Figueroa-Mendez and Rivas-Arancibia in 2015 have established that vitamin C 
effects on learning and memory are reliant on the redox balance state. This behaviour 
and distribution in humans allows the vitamin to act as a factor in a minimal of eight 
enzymes, within mammals, to defend a range of cells from oxidative stress in addition 
to the production of collagen (Wang et al. 2002; Valko et al. 2006; Hierro et al. 2013). 
Evidently these protective qualities of vitamin C make it imperative to fight against a 
diverse array of diseases.  
1.2 Cellular Acquisition and Accumulation of Vitamin C 
Several aspects, both endogenous and exogenous, impact vitamin C body levels, 
primarily vitamin C transporters that control the vitamin’s accessibility and plasma and 
tissue levels. This is in addition to a range of environmental influences and endogenous 
stresses, for example oxidative stress and disease (Ciocoiu et al., 2007). Vitamin C 
exists in plasma primarily in its reduced form, ascorbic acid, at concentrations in the 
normal range of 30-60 mM (Levine et al., 1996; Rivas et al., 2008; Elste et al., 2017). 
Humans require only a small concentration of the vitamin per day. Research has stated 
that humans need approximately 100 mg of the nutrient per day to allow for healthy 
plasma and tissue levels of the vitamin (Levine et al. 1996; Lee et al., 2005). This intake 
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per day means the plasma levels are approximately 50-100 μM and distributed white 
blood have concentrations between 1 to 2 mM (Johnston, 2009; Padayatty et al. 2003).  
Vitamin C performs the majority of its biological roles intracellularly therefore it is 
obtained by most cells from the plasma, a procedure that needs the involvement of 
certain transporters. The oxidised form of the nutrient is transported across cells via 
facilitated diffusion by the GLUT 1,3 and 4 glucose sensitive transporters, which 
protects mitochondria from oxidative injury (Huang et al., 2001; KC et al. 2005). DHA 
has a crucial responsibility in many cells since it can be used to regenerate AA.  
DHA is transported from the lumen of the small intestine and reduced to AA, which 
consequently distributes in the blood (Tu et al., 2017). Physiological research has 
indicated that blood concentrations of vitamin C only consists of <0.5% of DHA, due to 
its brief physiological half-life, with the remaining involving AA (Dhariwal et al. 1991; 
Song et al. 2002). This was verified when oxidised vitamin C was expressed in Xenopus 
laevis oocytes and recognised using an electrochemical detection method (Koshiishi et 
al. 1998; Rumsey et al. 2000). The reduced form crosses the plasma membrane via the 
Na+-dependent systems and the SVCT1 and SVCT2 transporters, which transport 
stereospecifically (Liang et al. 2001). The two SVCT’s are surface glycoproteins 
encoded by two different genes, which have been proven to be very similar in structure, 
with high sequence homology (Savini et al., 2007). They have distinct functional 
characteristics and specific tissue distribution which suggests that they hold separate 
physiological roles within the human body (Savini et al. 2007).   
Alongside the apparent competitive inhibition effects of glucose concentration on DHA 
transport, it is known that the SVCT family are the main vitamin C carriers within 
mammalian cells. At physiological pH, approximately 99.9% of ascorbate exists as a 
monovalent anion holding a negative charge, which inhibits it from dispersing through 
cell membranes (Jin et al., 2005). This emphasises the need for the two transporters, 
which permit intake of vitamin C into the gastro intestine and consequently into the 
cells (Omotayo et al. 2015). SVCT1 and SVCT2 both cotransport ascorbic acid and 
sodium down an electrochemical sodium gradient at a ratio of 1:2, which is sustained by 
K+/Na+ exchange systems (Seno et al., 2004). This specific transport is highly 
responsive to changes to certain factors such as temperature and pH (Liang et al., 2001; 
Wohlrab et al. 2017). Studies on Xenopus laevis oocytes and mammalian cells have 
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proven that SVCT1 and SVCT2 transport activity of ascorbate is only functional when 
they are activated by sodium (Tsukaguchi et al. 1999; Bürzle et al. 2013; Subramanian 
et al. 2016).  
1.3 The Human Sodium-dependent Vitamin C Transporters  
1.3.1 Genetics of the Human Vitamin C Transporters 
The general gene structures of the two transporters are very similar, with human SVCT1 
possessing 15 exons and human SVCT2 consisting of 17, with most exons being similar 
sizes. This has been proven through encoding cDNA’s which have been replicated for 
both proteins, taken from human cDNA libraries, allowing the two carrier structures to 
be mapped (Stratakis et al. 2000; Wang et al. 2000). The two transporters have distinct 
functional characteristics and specific tissue distribution which suggests that they hold 
separate physiological roles within the human body (Savini et al. 2007).  SVCT1 and 
SVCT2 are members to a family of nucleobase transporters, involving general purine 
permease (UapC), uracil transporter (UraA) and membrane-bound uracil permease 
(PyrP) (Faaland et al., 1998; Meintanis et al., 2000; Wilson, 2005; Savini et al., 2007; 
Lu et al., 2011). The two carriers have no structural homology with any other 
mammalian membrane transporter. SVCT1 and SVCT2 are encoded by the SLC23A1 
and SLC23A2 genes, respectively (McNulty et al., 2005). The SLC23A1 gene is 16,096 
bp long and maps to human chromosome 5q31.2–31.3 (Sotiriou et al., 2002). The 
SLC23A2 gene maps to chromosome 20p12.2– 12.3 and is ten times larger, at 158,398 
bp long(Clark et al., 2002). 
A putative structure for SVCT1 and SVCT2 has been calculated by hydropathy 
analysis. Kyte-Doolittle plots suggest that both transporters are trans-membrane (TM) 
proteins (Savini et al., 2007). The predicted structure holds 12 membrane-spanning 
domains, with the N- and the C-termini found on the cytoplasmic side of the membrane 
(MacDonald, Thumser and Sharp, 2002). The extracellular loop between the 7 and 8 
TM domains contains many conserved proline residues, that are required for 
arrangement, stability and transport efficiency (Liang et al., 2001). Several other 
conserved proline residues have been located within the TM and could potentially be 
significant for determining the protein structure (Liang et al., 2001).  
Expression of the two SVCT transport proteins is specific depending on the tissue and 
cell and is controlled by transcriptional regulation of the human solute carrier gene 
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family 23 (SLC23) (Michels et al.2013). In epithelial cells, SVCT1 and SVCT2 are 
expressed in the apical and basolateral membranes, respectively. Sodium-dependent 
vitamin C transporter 1 is expressed in the epithelial tissue of the kidney, intestine, liver, 
lung, and skin (Qiao and May, 2011). Within the kidney, SVCT1 is located in the brush-
border membrane of the proximal tubule where it controls uptake of ascorbic acid, 
consequently acting as a key part in maintaining whole body ascorbate levels (Wang et 
al. 1999). The SVCT2 protein is greatly expressed in the brain where it is crucial for 
upholding the high ascorbate levels required for brain function and growth (Meredith et 
al. 2011). 
The transporters can be distinguished due to their kinetic properties which have been 
proven to be functionally different. SVCT1 has an ascorbic acid Km higher than 
SVCT2 and a lower affinity for ascorbate meaning it is adapted to high capacity uptake 
of the vitamin from the diet (Savini et al. 2007). Sodium-dependent vitamin C 
transporter 2 is positioned in nearly every tissue and cell in the body (Michels et al. 
2013). It is categorised as a low capacity, high affinity transporter and can retain lower 
concentrations of ascorbic acid than SVCT1 (Obrenovich et al., 2006). Through studies 
using human cell lines and cells with over expressed cloned SVCT1 and SVCT2, it has 
been established that SVCT1 has an ascorbic acid transport Km of approximately 80-
200 uM and approximately 15-25 uM for SVCT2 (Godoy et al., 2007; Rivas et 
al.,2008). The greater vmax value for human SVCT1 can be linked to a higher turnover 
rapidity.   
At acidic pH, the transporters are unable to function at an optimum level, as shown 
through a reduced binding affinity for ascorbate (Shaghaghi et al. 2016). Both 
transporters are stereospecific and have an optimum pH of approximately 7.5 , which 
was measured at 22°C in transfected COS-1 cells, and displayed great specificity for L-
ascorbic acid rather than for its stereoisomer (Wang et al. 2000; Liang et al. 2001). 
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Table 1-1. Comparison of Characteristics of hSVCT1 and hSVCT2 
Characteristic hSVCT1 hSVCT2 
Gene Length 16,096 158,398 
Chromosomal Locus 5Q31.2-31.3 20P12.2-12.3 
Protein Length  598 amino acids 650 amino 
acids 
SNP’S 4 0 
Gene Structure 15 exons 17 exons 
Protein Mass 65-80 kDa 65-80 kDa 
Km (affinity) 65-252uM 8-69Um 
Vmax (Capacity) 8-15.8pmol 0.04-1.2pmol 
Localisation in Polarised 
Epithelia 
Apical Basolateral 
Optimum pH 7.5 at 22°C 7.5 at 22°C 
Distribution in Humans Kidney, Small Intestine epithelium, 
Colon and Liver 
Widespread 
 
1.3.2 Mutations in SLC23A1 and SLC23A2 
As a result of the direct contact of SVCTs with reduced vitamin C and their 
responsibilities in absorption and tissue accumulation, genetic modifications 
in SLC23A1 and SLC23A2 seem to have the biggest impact on human vitamin C in 
comparison to other genetic factors (Shaghaghi et al., 2016). Polymorphisms in the 
genes encoding the transporter proteins are greatly linked with plasma ascorbate levels 
and potentially effect tissue cellular vitamin C levels (Jimenez-Fernandez et al., 2012). 
Moreover, changes to genetic sequences of specific proteins that reduce oxidative stress 
including; haptoglobin, glutathione-S-transferases, affect ascorbate levels in the human 
body (Michels et al., 2013).  
One study has evaluated one splicing variant for SVCT1 which produced a protein 
holding an insertion of 4 additional amino acids localised in the extracellular loops that 
connects transmembrane domains 3 and 4 (Rivas et al., 2008). These studies revealed 
that this splicing variant was unable to make the transporter function correctly due to its 
inability to carry vitamin C (Wang et al. 1999; Eck et al. 2004). Another splicing variant 
has been expressed for SVCT2 which is lacking 345 base pairs from the coding 
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sequence. This concluded in a short protein of 525 amino acids which was not able to 
transport ascorbic acid and instead acted as an inhibitor. This protein inhibited the 
transport which is normally facilitated by SVCT2 and it also marginally inhibited 
SVCT1 functions through the development of protein- protein complexes (Liu et al. 
2001). 
More than 150 SNPs have been acknowledged in SLC23A1, with a minimum of four of 
the SNPs found in SLC23A1 located in the coding region (exons 3, 7, and 8), which 
causes one synonymous and three nonsynonymous alterations to the transporter (Gispert 
et al., 2000). All nonsynonymous polymorphisms created an operative SVCT1 protein, 
but each of these transporters displayed declines in ascorbate transport when expressed 
in Xenopus laevis oocytes (Corpe et al., 2010).A vigorous discovery for the influence 
of SLC23A1 genetic variation on plasma ascorbate levels was established by Timpson et 
al. 2010 in a multiple unit assessment in excess of 15,000 individuals within the United 
Kingdom. One of the SNPs researched was connected with regular, reproducible 
reduction in circulating vitamin C levels. Generally, for the population in this study, the 
genetic change was linked with a roughly 6 μM lower plasma or serum ascorbate 
concentration per allele. The considerable size of SLC23A2 means that variants in the 
genetic structure are comparatively recurrent and extensive (Maulén et al., 2002).  
Most of the SNPs investigated are either intronic or untranslated regions of SLC23A2 
and therefore do not directly modify the coding of the SVCT2 transporter (Smith, 
Visioli and Hagen, 2002). Contradictory to variations in SLC23A1, genetic alterations 
in SLC23A2 are not predicted to have a significant influence on ascorbate homeostasis 
in the circulation, as SVCT2 controls the tissue build-up the vitamin C from the plasma 
(Cahill and El-Sohemy 2009). 
1.3.3 N-Glycosylation 
Analyses indicate that hSVCT1 and hSVCT2 each have a 12-transmembrane structure 
with cytoplasmic C and N-terminal domains in addition to several consensus sites for 
glycosylation and phosphorylation (Subramanian et al., 2008). Both SVCT1 and 
SVCT2 have potential sites where N-glycosylation can occur within the extracellular 
loops, hSVCT1; Asn138 and Asn144 with hSVCT2 at; Asn188 and Asn196. The sites were 
located between the predicted transmembrane domains 3 and 4 and an additional site for 
hSVCT1, Asn230, found between TM 5 and 6. N-glycosylation has been proven to be 
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needed for transport functionality, targeting, folding, and stability of numerous 
transporters (Martı́nez-Maza et al. 2001; Tanaka et al. 2004; Zhou et al. 2005). 
 Subramanian et al, 2011 studied whether the transport functionality and targeting of the 
vitamin C transport proteins were affected within human hepatic liver cells when the N-
glycosylation sites were mutated. The results showed that removal of these individual 
sites considerably reduced the expression and therefore the ascorbate uptake by the 
hSVCT1 and hSVCT2 mutants. The research also proved that mutations of the N-
glycosylation sites particularly affected the cell surface targeting of the transporters. 
Although both transporters had restricted ascorbate uptake, they reacted differently to 
the mutations, which may have been caused by separate mechanisms. SVCT1 
alterations caused a decreased quantity of the transporter being present on the cell 
membrane compared to SVCT2 whose localisation did not change (Subramanian et al. 
2008). The study also indicated that glycosylation may control the allocation of SVCT1 
both on cell surface membrane and inside the cell. The results concluded that 
glycosylation is crucial for the functional expression for both ascorbate transporters.  
1.3.4 Phosphorylation 
The knowledge of the protein sequences of the two transporters has revealed that they 
hold five protein kinase C (PKC) phosphorylation sites. These are located on the 
cytoplasmic surfaces of the proteins. The PKC activating agent PMA, has found to 
decrease ascorbate uptake by the two transporters when tested in oocytes containing 
hSVCT1 and hSVCT2 (Takanaga et al. 2004). For SVCT1 the decrease in Vmax is 
linked with a change in dispersal from the cell surface membrane to inside the cell 
which contrasts with SVCT2 which remained in the plasma membrane. Reidling et al 
studied the outcome when all five PKC sites were altered in SVCT1 and SVCT2. Each 
site was changed from a threonine or serine to an alanine.  They found that changing 
just a singular amino acid did not impact the reduction in ascorbic acid uptake or 
transport. Indications suggest that other factors such as protein-protein mechanisms may 
be influencing the level of affects that PMA has on the transporters. 
The transporters both demonstrate changes in transport capability upon PKC instigation, 
particularly SVCT1 (Wu et al. 2007; Figueroa-Méndez and Rivas-Arancibia 2015). 
These studies have found that it is probable that PKC activation potentially leads to 
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internalization of hSVCT1 which is thought to be reversible, however it does not affect 
the hSVCT2 membrane expression (Reidling et al., 2008).  
1.3.5 Pathways which Regulate SVCT 
Many contributing factors alter the signal transduction pathways that mediate ascorbate 
uptake, including increased age. Research undertaken by Michels et al (2003) showed 
that SVCT1 mRNA falls by approximately 45% in rat hepatocytes, aged 24-26 months, 
compared to juvenile rats, aged 3-5 months. Within humans, the independent functions 
of the two transporters are essential for transport and survival. Therefore this drop in 
SVCT1 mRNA will cause the carrier to be defective, which can be fatal. The loss of this 
protein for humans as they get older can consequently give an indication to the decline 
in ascorbate levels, caused by altered signalling.  
Disturbance to the signalling pathways of SVCT transporters can lead to numerous 
problems with the uptake of ascorbate. Reduced ascorbate concentrations have been 
linked to a decrease in vitamin E, glutathione, levels within the body and ultimately 
causes a disruption in antioxidant protection (Ulrich-Merzenich et al. 2007; Yousef et 
al. 2012). Reduced defence against antioxidants allows an opportunity for an increase in 
production of pro-oxidant cells inside the body, which increases with age (Gess et al. 
2013; Sorice et al. 2014). This increase in pro-oxidants can potentially increase the 
activation of PKC, which can lead to a reduction in the transport capacity of SVCT1. 
1.4 Vitamin C and Degenerative Diseases 
Vitamin C is widely used as a therapeutic agent in many diseases and disorders. Recent 
pharmacokinetic data has improved the knowledge relating to vitamin C transport and 
its links with the prevention and treatment of cancer. Since the 1970’s research has 
reviewed the nutrient as a cancer remedy and have investigated the effects of high-dose 
of AA on the growth and progression of tumours and the mechanisms behind the anti-
cancer effect (Chambial et al., 2013).  
High levels of vitamin C in the blood is beneficial as the nutrient increases the build-up 
of hydrogen peroxide (H2O2) which is preferentially toxic towards tumour cells (Chen 
et al., 2007). Individuals with cancer who are given vitamin C intravenously will see 
plasma levels elevate as the injection bypasses the intestinal absorption system 
(Harrison, 2012). This is valuable as high doses have been linked to slowing the growth 
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and spread of prostate, pancreatic, liver and colon cancer. It is also thought to be 
beneficial in curing individuals with cancer by combining high doses of AA with 
chemotherapy, making the treatment more effective (Korok et al., 2000; Stephenson et 
al., 2013). Specific treatments which have increased efficiency when combined with 
high dose of AA include; arsenic trioxide for ovarian cancer cells and gemcitabine in 
pancreatic cancer cells (Qazilbash et al., 2008; Monti et al., 2012). Evidence has been 
accumulating which indicates that intravenous vitamin C may enhance the quality of 
life of cancer patients, through reduced pain and the need for pain relief medication.  
The antioxidant functions of AA are essential for optimal human health in addition to its 
anti-inflammatory properties and inhibition of tumour metastasis. Absence of the 
nutrient would increase the levels of reactive oxygen species in the body which 
stimulates apoptosis, inflammation and initiate interference to genes which facilitate cell 
adhesion (Jagetia et al., 2007; Sangani et al 2015). Obstructions to the vitamin C 
transporters can instigate the onset of numerous degenerative diseases such as 
cardiovascular disease (CVD) which has resilient oxidative damaging factors (Yun et 
al., 2015). It is evident that sufficient levels of vitamin C and its specific mechanisms of 
transport are crucial for human health and the prevention of numerous harmful diseases.   
1.5 Vitamin C Inhibition 
SVCT1 and SVCT2 are low abundance transport proteins and consequently are yet to 
be quantified by binding or coupling. Vitamin C and flavonoids are both substances 
widely found within numerous fruits and vegetables that humans ingest (Awad et al., 
2001). The reactions of flavonoids with the vitamin C transporters have been 
investigated as they are predicted to reduce the level of ascorbate uptake within 
mammals (Berger et al., 2003; Caprile et al., 2009). Song et al, 2002 investigated 12 
flavonoids and tested them against SVCT1 transport activity within Xenopus laevis 
oocytes and Chinese hamster ovary cells. They found that certain flavonoids have novel 
regulatory abilities that reduce or inhibit ascorbate uptake. They founded that the most 
potent of all the flavonoids were the flavanols, of which Quercitin is found in most 
plant-based foods. When tested Quercetin acted as a non-competitive inhibitor which 
reduced SVCT1 transport efficiency (Biondi et al., 2006). SVCT1 did not transport the 
flavonoid and the inhibition appeared reversible. Quertcetin appeared the most effective 
inhibitor due to its structure. The flavonoids ability to reduce ascorbate transport took 
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place from the intestinal lumen into the cells (Kuo, Morehouse and Lin, 1997; Rietjens 
et al., 2002). It is evident that the effects of the flavonoids can greatly influence the 
ascorbate bioavailability, consequently this may alter human daily requirement of 
vitamin C.  
1.6 Drug Transport in relation to SVCT1 and SVCT2  
The efficiency of certain therapeutic drugs are frequently limited by negative biological 
or pharmacokinetic influences including, poor bioavailability or restricted water 
solubility. Plasma membrane proteins are freely available to drug molecules due to their 
localisation on the cell surface (Boyer et al., 2005). By joining these drugs with the 
substrates of their appropriate complementary transporter proteins, drug uptake and oral 
accessibility can be considerably improved (Luo et al. 2011). It has been established 
that both vitamin C transporters have the capability to transport other compounds, with 
the requirement of specific structural conditions (Rumsey et al. 1999; Luo et al. 2008). 
This suggests that the two ion transporters may have the ability to be areas for site 
specific drug delivery.  
Studies by Dalpiaz et al, 2005 investigated the results of conjugating an anticonvulsant 
drug with ascorbic acid. The outcome showed that individually the drug does not co-
operate with SVCT2, nonetheless in the presence of AA the drug was able to interact 
and showed anticonvulsant action, enhancing the delivery. These results will provoke 
further research into the vitamin C transporters and their interactions with specific 
drugs. If these predictions are correct this knowledge can be utilised for designing and 
testing of new drugs and medicines.  
1.7 Rationale 
Establishing how specific types of cells transport vitamin C is essential in recognising 
how vitamin C homeostasis is controlled across mammalian bodies. Over the past 
decade substantial developments have been made in our understanding of the systems 
by which vitamin C distributes into cells. Nevertheless, little knowledge is 
acknowledged on the mechanisms which control the actions and localisation of these 
transporter proteins.  
Extending our knowledge on the structural operating mechanisms of hSVCT1 and 
hSVCT2 gives the opportunity to manage or influence the cell surface presence of these 
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proteins. This could be greatly beneficial to certain people whose health is affected by 
low ascorbate plasma concentrations as a result of ; genetic, environmental and physical 
factors. An advanced understanding of these mechanisms would provide the 
opportunities for tissue specific drug delivery. This would be highly important for the 
pharmaceutical drug design and medicinal treatment of patients as it could aid the 
development of new therapeutic medications.  
Pinpointing the specific sites on SVCT1 and SVCT2 using approaches of mutagenesis 
may be important for a better understanding of membrane interaction mechanisms. This 
may be used for further study into how certain residues can influence the membrane 
targeting of each transporter. By analysing each protein and nucleotide sequence and 
consequently altering certain amino acids, it will provide an insight into whether these 
sites are influential in the mechanisms of the transporters. The created mutants will 
support future studies on the mechanisms that control targeting of SVCT1 and SVCT2. 
It will also aid our understanding on how the proteins will react and be affected by drug 
competition, such as medicines entering the human body.  
1.8 Aims and Objectives  
The aim of this master’s research is to prepare a starter for future evaluation of the 
molecular recognition sites of the human vitamin C transporters through studying the 
expected crucial sites on the proteins. To accomplish this aim the following objectives 
were designed: 
Objective 1: To assess hSVCT1 and hSVCT2 coding sequences and protein sequences 
with the use of bioinformatics tools and literature reviews. This highlights area 
including reading frames that are likely to play a factor in molecular recognition.  
Objective 2: To conduct PCR based site specific mutagenesis on hSVCT1 and 
hSVCT2’s coding regions that are predicted to be important.  
Objective 3:  To obtain molecular clones through transformation methods and colony 
growth into phSVCT1 and phSVCT2 plasmids. 
Objective 4: To confirm the mutations by sequencing analysis, assisted with 
bioinformatic approaches.  
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2.0 Materials and Methodology 
2.1 Materials 
All reagents used were, where appropriate, molecular biology grade and are listed in 
Table 2-1. Details of this use of these enzymes are explained in Table 2-2 and the main 
enzymes used are listed in Table 2-3. Maps of the host plasmids are shown in Figure 2-
1. All resources including pipette tips, beakers and flasks were all autoclaved prior to 
us. COSHH and Record of Risk Assessment forms can be found in Appendix I and II. 
Due to the nature of this research a variety of commercial kits were utilised. The 
QIAPrep- spin MiniPrep Kit to extract hSVCT1, hSVCT2 and JM109, the QIAquick 
PCR Purification Kit to purify PCR products and the QIAquick DNA Gel Extration Kit 
used following gel electrophoresis. See Table 2-1 for all commercial kits, their 
manufacturers and catalogue numbers.  
The necessary enzymes included: T4 DNA Ligase from New England Biolabs, Taq 
Polymerase from Promega Ltd, Dpn1 from New England Biolabs, restriction 
endonuclease XbaI and restriction endonuclease HindIII both from Thermo Fisher. See 
Table 2-1 for all enzymes, manufacturers and catalogue numbers. 
Throughout the research project a number of chemicals were regularly used to 
undertake the laboratory procedures these include: Ethanol Absolute, Agarose Powder, 
Tryptone, Yeast Extract, Agar Powder, 1kb Ladder, 5X Flexi Buffer, Magnesium 
Chloride solution, NEB Buffer 2, BSA, SYBR Safe gel stain and ampicillin 100mg/ml. 
See Table 2-1 for a list of all chemicals, manufacturers and catalogue numbers and see 
Table 2-2 for the application of each chemical.  
For the protocols to be effective the following equipment and machinery were used: 
Bio-Rad ChemDoc MP Imaging System for gel electrophoresis, JB Nova water bath, 
NanoDrop 2000 Spectrophotometer, Shimadzu Spectrophotometer UV-1800, Heraeus 
centrifuge, centrifuge S3430R, 800W Large Autoclave, Orbital Shaker and Benchmark 
Heated Magnetic Stirrer.  
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Table 2-1. List of reagents and their manufacturers.  
# Reagent Manufacturer Catalogue 
Number 
Contact 
1 1kb Ladder Promega G5711 www.promega.com 
2 5X Green GoTAQTM  
buffer 
Promega M7911 www.promega.com 
3 10X Buffer (1-4) NEB B7000S www.neb.com 
4 Agar FS BP1423-
500 
www.fishersci.com 
5 Agarose FS V3121 www.fishersci.com 
6 Ampicillin Sigma-Aldrich A9393 www.sigmaaldrich.com 
7 Bacto-tryptone FS BPE1421-
500 
www.fishersci.com 
8 Bacto-yeast extract FS BP1422-
500 
www.fishersci.com 
9 Bovine Serum Albumin NEB  B9000S www.neb.com 
10 ddH20 Acros Organics 345470250 www.acros.com 
11 dNTP Roche 119690640
01 
www.roche.com 
12 Dpn1 NEB R0176S www.neb.com 
13 EDTA FS BP120-500 www.fishersci.com 
14 Ethanol FS BP2818-
500 
www.fishersci.com 
15 GoTaq Polymerase  Promega M3001 www.promega.co.uk 
16 HCl (Concentrated) FS SA49 www.fishersci.com 
17 HindIII Enzyme ThermoFisher ER0501 www.thermofisher.com 
18 Isopropanol FS BP2618-
212 
www.fishersci.com 
19 MgCl2 Promega A3511 www.promega.com 
20 NaCl BDH Lab 
Supplies 
S271-500 www.uk.vwr.com 
21 QIAquick Gel 
Extraction Kit (50) 
QIAGEN 28704 www.QIAGEN.com 
22 QIAquick PCR 
Purification Kit (50) 
QIAGEN 28104 www.QIAGEN.com 
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23 QIAprep Spin Miniprep 
Kit (250) 
QIAGEN 27106 www.QIAGEN.com 
24 Sepharose Sigma-Aldrich CL6B200 www.sigmaaldrich.com 
25 Shrimp Alkaline 
Phosphatase 
NEB M0371S www.neb.com 
26 SYBR Safe DNA gel 
Stain 
Invitrogen S33102 probes.invitrogen.com 
27 T4 DNA Ligase reaction 
buffer 
NEB B0202S www.NEB.com 
28 Tris Acetate FS BPE1331-1 www.fishersci.com 
29 Tris Base FS BP152-1 www.fishersci.com 
30 XbaI Enzyme ThermoFisher IVGN0126 www.thermofisher.com 
31 Yeast Extract Sigma-Aldrich 70161-50G www.sigmaaldrich.com 
 
Table 2-2. Uses of Reagents from Table 2-1. 
# Use 
1 Loaded during agarose gel electrophoresis to approximate weight of DNA 
2 Loading dye for agarose gel electrophoresis (Enables DNA in samples to sink to 
the bottom of the wells) 
3 Restriction analysis and overhanging ends formation 
4 Used to make agar plates for E.coli DH5α (phSVCT): Selection/recovery and 
transformation 
5 Used to make a gel for electrophoresis 
6 Added to LB agar 
7 To make LB medium and agar plates 
8 To make LB medium and agar plates 
9 Used during restriction digest to stabilise certain enzymes and to prevent 
adhesion 
10 To make buffers, media, agar plates and dilutions 
11 Component used during PCR 
12 Used to cut methylated DNA 
13 To make TE buffers for dilutions 
14 Sterilisation of glass transmitter used in transformation 
15 Component of PCR 
16 To make TRIS-Cl, used as elution buffer in certain gel extractions and to make 
TE buffers 
17 Component which cuts sequences during restriction digest 
18 Gel extraction of DNA (Increases the yield of DNA fragments) 
19 Component used during PCR 
20 Used to make LB agar plates 
21 Extraction of PCR products  
22 Purification of PCR products 
23 Cell lysis and Extraction of phSVCT plasmids 
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24 Used during purification of PCR products 
25 Prevents religation of linearized plasmid DNA 
26 Used to dye the agarose gel 
27 Ligation of fusion products with the vector 
28 To make TE buffers and TAE buffers for Agarose Gel Electrophoresis 
29 To make TE buffers and TAE buffers for Agarose Gel Electrophoresis. 
30 Component which cuts sequences during restriction digest 
31 Component which is used to make LB plates 
 
Table 2-3. Enzymes Used 
 
 
     
E.coli Strain Chromosomal Genotype Source Use 
DH5α 
(phSVCT1) 
fhuA2, ∆ (argF-lacZ), 
U169, phoA, glnV44, Ø80 ∆ 
(lacZ),MI5, gyrA96, recA1, 
relA1, endA1,thi-1, hsdR17.    
( hSVCT1 cloned in 
pcDNA3.1, with the V5 
epitope and 6-histidine tail.) 
Liang, W-J, 
(NEB; 
Liang et 
al.2017) 
Source of plasmid 
phSVCT1 
DH5α 
(phSVCT2) 
fhuA2, ∆ (argF-lacZ), 
U169, phoA, glnV44, Ø80 
∆(lacZ),MI5, gyrA96, 
recA1, relA1, endA1,thi-1, 
hsdR17. 
( hSVCT2  cloned in 
pcDNA3.1, with the V5 
epitope and 6-histidine tail.) 
Liang, W-J, 
(NEB; 
Liang et 
al.2017) 
Source of plasmid 
phSVCT2 
MC1061 K-12 F– λ– Δ(ara-leu)7697 
[araD139]B/r Δ(codB-
lacI)3 galK16 galE15 e14– 
mcrA0 relA1 rpsL150(StrR) 
spoT1 mcrB1 hsdR2(r–m+) 
Liang, W-J, 
(NEB; 
Liang et 
al.2017) 
Sub-cloning of 
hSVCT cDNA  
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Table 2-4. E.coli Strains Used 
 
 
 
 
 
 
 
E.coli Strain Chromosomal Genotype Source Use 
DH5α 
(phSVCT1) 
fhuA2, ∆ (argF-lacZ), 
U169, phoA, glnV44, Ø80 ∆ 
(lacZ),MI5, gyrA96, recA1, 
relA1, endA1,thi-1, hsdR17.    
( hSVCT1 cloned in 
pcDNA3.1, with the V5 
epitope and 6-histidine tail.) 
Liang, W-J, 
(NEB; 
Liang et 
al.2016) 
Source of plasmid 
phSVCT1 
DH5α 
(phSVCT2) 
fhuA2, ∆ (argF-lacZ), 
U169, phoA, glnV44, Ø80 
∆(lacZ),MI5, gyrA96, 
recA1, relA1, endA1,thi-1, 
hsdR17. 
( hSVCT2  cloned in 
pcDNA3.1, with the V5 
epitope and 6-histidine tail.) 
Liang, W-J, 
(NEB; 
Liang et 
al.2016) 
Source of plasmid 
phSVCT2 
MC1061 K-12 F– λ– Δ(ara-leu)7697 
[araD139]B/r Δ(codB-
lacI)3 galK16 galE15 e14– 
mcrA0 relA1 rpsL150(StrR) 
spoT1 mcrB1 hsdR2(r–m+) 
Liang, W-J, 
(NEB; 
Liang et 
al.2016) 
Sub-cloning of 
hSVCT cDNA  
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2.2 Methodology 
2.2.1 Strategy One 
To perform the laboratory experiments a relative efficient strategy had to be designed 
and followed. This strategy is outlined in Figure 2-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. Flowchart of Overall Research Strategy 
 
1. Background research on 
hSVCT1 and hSVCT2 and how 
they independently transport 
vitamin C around mammalian 
bodies. 
2. Design of primers based upon 
varying mammalian vitamin c 
transporters. Amino acid 
changes in the primary 
sequences. 
3. Extraction of the plasmids 
from phSVCT1 and phSVCT2. 
Streaking of plates and 
inoculation of chosen colonies. 
4. Purification of DNA plasmids 
through MiniPrep Spin Kit. First 
step PCR where amplification of 
SVCT1 and SVCT2 occurs.  
5. Fusion PCR of the overlapping 
strands made from the 
amplification. Gel 
electrophoresis to visualize the 
results.  
6. Double restriction digest of 
fusion PCR products and purified 
plasmids, using the restriction 
enzymes XbaI and HindIII. Gel 
electrophoresis to visualize the 
results. 
7. Ligation of the fusions from 
Step 6 with the digested vector.  
8. Transformation where the 
DNA is introduced into the E.coli 
cells. Followed by selection of 
certain colony for growth.  
9. Extraction of the plasmid 
followed by external sequencing 
to confirm success of the project 
and growth of mutants. 
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2.2.2 Strategy Two 
A new strategy was designed for this project when the initial outline was not successful. 
The improved strategy was effective and more efficient. Strategy two is outlined in 
Figure 2-2. 
 
 
 
 
 
 
Figure 2-2. Flowchart of strategy two which was utilised to complete the project. 
 
 
 
1. Background research on hSVCT1 
and hSVCT2 and how they 
independently transport vitamin C 
around mammalian bodies.
2. Design of primers based upon 
varying mammalian vitamin c 
transporters. Amino acid changes in 
the primary sequences.
3. Extraction of the plasmids from 
phSVCT1 and phSVCT2. Streaking 
of plates and inoculation of chosen 
colonies.
4. Purification of DNA plasmids 
through MiniPrep Spin Kit. First 
step PCR where amplification of 
SVCT1 and SVCT2 occurs. No 
flanking primers used only the 
muatated sequences.
5. Dpn1 treatment to PCR 
products in preparation 
for transformation.
6. Transformation where the DNA is 
introduced into the E.coli cells. 
Followed by selection of certain 
colony for growth. 
7. Extraction of the plasmid 
followed by external sequencing to 
confirm success of the project and 
growth of mutants.
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Figure 2-3. Plasmids phSVCT1 and phSVCT2: Mammalian Expression Vectors 
Used as Parent Clones and Vectors. The plasmid maps were designed using Redasoft 
Plasmid 1.1 software. hSVCT1 and hSVCT2 were cloned into the plasmids pcDNA3. 
Primer binding sites have been indicated in green. 
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2.2.3 Primer Design  
 
Primers were designed based upon the amino acid coding sequences of the two vitamin 
C transporters. The primers are an important constituent used during the polymerase 
chain reaction which allow the gene, phSVCT, to be amplified. They also facilitate in 
the alteration of restriction sites found on the vector and gene. The membrane sequences 
were compared between numerous organisms, particularly among those who can 
naturally synthesise vitamin C against those who have to consume or ingest the nutrient 
to survive. A total of five primers sets were designed for each of the transporters, 
centred upon altering specific amino acids which appeared to be crucial in their primary 
structures. The coding sequences of the transporters were found using NCBI databases 
and the open reading frames were identified using the lalign program. The primers were 
created for replacing one amino acid with another, based on their charge, properties and 
location on the protein sequence. To design effective primers, it is crucial that the 
sequences meet the specific criteria to enable them to anneal to specific regions. The 
following formula was utilised which allowed the correct annealing temperatures (Ta) 
and melting temperatures TM for the primers;  
Tm= 81.5 + 41 x CG% -675/mers 
Ta= Tm-5°C 
Adhering to the criteria, primer was created between 18-25 nucleotides long and had 
calculated annealing temperature between 58-71°C for differing PCR reactions. A 
forward and reverse primer was designed for each change in amino acid, which were 
constructed with less than 1°C difference between annealing temperatures. The 
designed primers were diluted with T10E1 prior to any use during the laboratory process. 
2.2.4 Preparation of Essential Solutions, Reagents and Buffers 
 
Tris(hydroxymethyl)aminomethane – hydrochloride (TRIS-HCl) is designed to keep 
solutions within a pH range of 7.0 to 9.0. To make a 1M solution, 121.14g of Tris was 
mixed to 800ml of deionised water on a hot plate until fully dissolved, this was then 
combined with 54ml of 37% HCl, which caused the pH of the solution to reach 8. This 
specific value was measured using a pH indicator and at pH8 DNAase is prevented from 
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reacting any further. The final solution was subsequently autoclaved under a media 
setting, guaranteeing sterilisation. 
Ethylenediaminetetraacetic acid (EDTA) was also formed as it is an important 
component in inactivating enzymes. To make a 0.5 Molar solution of EDTA with a pH 
near 8.0, 93.06g of EDTA was added to 500ml of deionised water and 11.7g of NaOH 
pellets were dissolved into the solution to increase to pH 8. The solution was thoroughly 
mixed using a magnetic stirrer and the pH was confirmed with a pH indicator. At this 
pH level, the solution was then autoclaved until the solution became transparent. 
T10E1 ( 10mM Tris HCl pH8.0, 1mM EDTA) is needed for diluting both primers and 
uncut DNA and was made up to 1ml each time. 2µl of EDTA was added to 10µl of 
Tris-HCl and 988µl of distilled water into a 1.5ml Eppendorf. 
To make Luria-Bertanin (LB) ampicillin agar, 100µg/ml of ampicillin stock solution 
was mixed to the LB agar media constituents, see Table 2-4, this occurred after the 
components had been autoclaved, mixed on a heat block and cooled (Maniatis, 1989). 
Table 2-5. Constituents used to make LB agar. 
Constituent Mass (grams) 
Tryptone 10 
Yeast Extract 5 
Sodium Chloride (NaCl) 10 
Agar 15 
 
2.2.5 Culture of Bacteria Containing SVCT Plasmids  
 
The host bacteria, DH5α (phSVCT1) and DH5α (phSVCT2), were selected from storage 
in deep freeze (-80oC) and were streaked onto the prepared ampicillin LB plates under a 
tungsten loop to separate the pure strain from a single species of the bacteria. The 
streaking took place using a Bunsen burner, to ensure that all equipment was sterile 
reducing the chance of contamination. This technique is used to obtain a single colony 
of bacteria and identifies potential contamination. These streaked plates were then 
incubated for approximately 14 hours, upside down at 37°C and subsequently at room 
temperature for 30 minutes to allow for sufficient growth. All plates were stored at 4 oC 
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for a maximum of two weeks. After the first stage of incubation, an appropriate single 
colony was selected from the plate and inoculated into a separate 50ml Falcon tube 
containing liquid LB medium and ampicillin. These colonies were then grown at 37°C 
for 18 hours, with continuous shaking (250 rpm). 
2.2.6 DNA Quantification with NanoDrop 
 
The DNA Thermo Scientific NanoDrop 2000 Spectrophotometer was utilised which 
uses UV and visible light to determine the concentrations of the nucleic acids and to 
quantify the amount of DNA in the samples. To begin, 1µl of water was added acting as 
‘blank’ testing to calibrate the machine. To check the absorbance of the whole DNA 
sample 1µl of the required plasmid DNA was used. The concentration results indicated 
whether a dilution to the plasmid was suitable for the PCR process. This was subject to 
the 260/280 ratio; which should be between 1.80-2.0 and the OD 260 reading that was 
required between 0.20-0.80. The final nucleic acid concentration must be no more than 
50µg for double stranded DNA. 
2.2.7 QIAprep@ Spin Miniprep Kit  
 
The QIAprep Spin Miniprep Kit (Qiagen) was utilised for purifying the SVCT1 and 
SVCT2 plasmid DNA by isolating certain plasmids from bacterial cells. The kit used 
silica-gel-membrane technology to bind DNA, from which the DNA can be eluted with 
an elution buffer or water. 50ml of each sample was formed from this protocol and the 
draw through was pipetted into a new 1.5ml Eppendorf and eluted in T10E1 buffer. 4µl 
of the DNA sample was then transferred into a new Eppendorf ready to be mixed with 
1µl of GoTaq5X Green Buffer, in preparation for screening gel electrophoresis. 
2.2.8 Polymerase Chain Reaction- PCR 
 
To begin the cloning procedure, 10 fragments were amplified in total; 5 from phSVCT1 
and 5 from phSVCT2. The primers needed for first step PCR were initially diluted 
accordingly into the prepared T10E1, depending on their weight. The preparation for the 
PCR took place using the constituents shown in the Table 2-5 and a specific programme 
was designed based upon the annealing temperatures of the created primers. During the 
running programme the annealing temperature was maintained at 60.0°C, this was 
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calculated as the average between all the samples, which is important as efficiency and 
specificity of PCR are strongly affected by the annealing temperature. The course 
comprised of 95°C for 5 mins and then 28 cycles each at; 94°C for 1 min, an extension 
of 60°C for 30 seconds, 72°C for 2 mins and finally the last extension of 72°C for 4 
mins. 
Table 2-6. Constituents used for PCR. 
Constituent Volume ( µl) Final Concentration 
dH20 33.5  
5X Flexi Buffer 10 1X 
1mM dNTP 1 1mM 
25mM MgCl2 2 0.2µM 
10µM Forward Primer 1 2 µM 
10µM Reverse Primer 1 2 µM 
DNA Sample 1  
GoTaq DNA Polymerase 0.5 2.5units/ 50µl 
 
In preparation for PCR to successfully generate specific DNA target regions, a solution 
of 10mM dNTP was formed. This was accomplished using 10µl of dATP, dDTP, dCTP, 
dGTP joined with 60µl of deionised water. This 100µl solution was then equally 
divided into falcon tubes and diluted further at a 1:9 ratio so that 1mM of dNTP could 
be used as a PCR constituent.  
2.2.9 QIAquick PCR Purification Kit 
 
QIAquick Kit is used prior to fusion PCR to purify the samples. The purification 
process eliminates primers, nucleotides, enzymes, salts, agarose, ethidium bromide, and 
other impurities from DNA samples. Silica-membrane equipment removes the 
complications and difficulties related with loose resins and slurries. The QIAquick kit 
uses a simple bind-wash-elute process. 
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2.2.10 Sepharose Purification 
 
Sepharose CL-6B 200 is used to separate media and resins due its extensive 
fractionation ranges making it appropriate for characterising or cleaning up samples 
holding components of diverse molecular weights. The Sepharose beads were used 
following primer PCR to ensure that a high level of purification took place to remove 
any remaining impurities, including salts and primers. 15-20ml of Cl-6B 200 was 
poured into a falcon tube and placed into the refrigerated Denley BR401 centrifuge and 
span at 3000rpm for 10 minutes. The volume of supernatant was then recorded and 
removed and an equal volume of T10E1 was added. This process was repeated a further 
three times until a large volume of supernatant had been removed. To form a filter, glass 
beads were added to a cut 100ul pipette and approximately 750ul of the prepared CL-6B 
200 mixture was added. This was inserted into an Eppendorf and spin column and span 
in a centrifuge at 9000rpm for 10 minutes until no aqueous solution remained. 45ul of 
the DNA sample was added to the spin column and centrifuged providing 
approximately 40ul of pure DNA remaining.   
2.2.11 Dpn1 Treatment 
 
The restriction enzyme Dpn1 is utilised after PCR due to its ability to digest methylated 
GATC sites. 1ul of the enzyme Dpn1 was added to the PCR samples alongside 5.5ul of 
1XCutSmart®Buffer. The samples were then placed into the incubator for 20 minutes at 
80°C to heat shock the enzyme and prevent any further reactions.  
2.2.12 Fusion Polymerase Chain Reaction  
 
Fusion PCR involves two parallel PCR amplifications from plasmid templates. PCR 
fusion of the amplified fragments from the first step PCR occurred through a single 
overlap extension occurring on PCR fragments from the parallel reactions. The first 
amplification used 10 parallel reactions, where 5 overlapping regions on each plasmid 
took place. The fusion PCR took place using a programme which was similar to the 
initial PCR setting. The lid temperature was also maintained at 110.0°C with an 
annealing temperature of 60°C. The programme ran using 28 cycles; 95°C for 5’0”, 
94°C for 1’0”, an extension of 60°C for 30”, 72°C for 4’30” and a concluding extension 
of 72°C for 4’30”. Following each PCR procedure, gel electrophoresis took place using 
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a 1.5 % w/v agarose gel, which was left to proceed for 40 minutes at 70V. Those bands 
which were required were extracted from the gel using a QIAquick Gel Extraction Kit 
and were consequently purified.  
Table 2-7. Constituents and volumes used for Fusion PCR 
Constituent Volume ( µl) Final Concentration 
dH20 33.5  
5X Flexi Buffer 10 1X 
1mM dNTP 1 1mM 
25mM MgCl2 2 0.2µM 
10µM Forward Primer 1 2 µM 
10µM Reverse Primer 1 2 µM 
Primary PCR DNA 
Sample 
1  
GoTaq DNA Polymerase 0.5 2.5units/ 50µl 
2.2.13 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was run following the completion of most stages of the 
practical project as it separates DNA by size for visualization and purification of the 
samples (Smith, 1996). The agarose gel was made using 40ml of 1X TAE Buffer (using 
diluted 50X TAE Buffer), 64g of genetic analysis grade agarose .The components were 
mixed together in a microwavable flask and then heated until clear and fully dissolved. 
Once slightly cooled, 4µl of SYBR Safe DNA gel stain is added which binds to the 
DNA and allows you to visualize the DNA under UV light. The agarose was then 
poured into a loading tray with a well comb in place and left to set for 20 minutes at 
room temperature. The agarose gel at 1.5% w/v, was loaded with 5X Green GoTAQTM 
buffer as a loading dye. To create a 1kb ladder, required for agarose electrophoresis gels, 
100µl of promega 1kb ladder was added to 100µl of 5X Green GoTAQTM buffer and 
300 µl of T10E1.  5µl of a 1kb DNA ladder was loaded alongside the experimental 
samples in each gel and was run at 70V for 40 minutes. To represent the results from 
the gel electrophoresis a ChemiDocTM MP Imaging System is utilised to analyse and 
easily quantify the samples, the machine uses a camera and UV-and white light 
illumination.  
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2.2.14 Restriction Digest  
 
Restriction digest took place with the use of phSVCT1 and phSVCT2 vectors and 
fusion fragments. This allowed the DNA molecules to be cut into smaller pieces with 
the use of restriction endonucleases, preparing the DNA for analysis. The chosen 
restriction enzymes, XbaI and HindIII cut the DNA into segments at specific restriction 
sites. The restriction digests were arranged using the components shown in Table 2-7. 
and the samples were then left in an incubator at 37°C for approximately 3 hours and 
subsequently stored within the freezer. 
Table 2-8. Constituents and volumes used for Restriction Digest 
Constituent Volume (µl) 
dH20 37 
10X NEB Buffer 2 5 
BSA (10mg/ml) 1 
Plasmid DNA/ PCR DNA 5 
Enzyme (20 units/ µl) 2 
 
2.2.15 Making Competent Cells 
 
In preparation for transformation the strain JM109 was grown on LB ampicillin 
prepared plates by streaking the strain four times in a certain pattern, using a d-loop and 
a Bunsen burner for sterilisation. The plates were left in the incubator overnight at 37°C 
for approximately 16 hours at 2500rpm to allow a sufficient number of colonies to 
grow. Following the growth of JM109 an individual colony was chosen and placed into 
the media using the d-loop, under sterilised conditions. The colony was inoculated 
overnight held within a flacon tube and shook in the orbital shaker at 250rpm at 37°C 
until the solution turned cloudy. Following the inoculation of JM109, 250ul of the 
competent cells were pipetted into 25ml of LB media and placed into the orbital shaker 
for a further 2 hours, at the same conditions. The mixture was then measured for 
absorbance using a Shimadzu UV-1800 Spectrophotometer which gave a log phase 
reading at A600 of 0.2552Abs. The culture was then chilled on ice and 1ml of cells was 
harvested by quick centrifuging at 8000rpm for 2 minutes at 4°C. The supernatant was 
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then discarded and the cells were re-suspended in 500ul of ice cold sterile calcium 
solution (50mM CaCl2, 10mM Tris HCl, pH 8.0).  The suspension was placed into an 
ice bath for 15 minutes and centrifuged at room temperature for 1 minute at 10,000 rpm. 
The supernatant was removed and to conclude the cells were re-suspended in 66ul the 
calcium solution.  
 2.2.16 Transformation 
 
7µl of the plasmid DNA mixture was added to 200 µl of the competent cells on ice and 
was then left to incubate at 37°C for 20 minutes. The DNA mixture was then heat 
shocked at 42°C, which occurred using a water bath for two minutes, and the samples 
were instantly transferred straight back onto ice for a further 2 minutes. Each sample 
was added to 330 µl of SOC media (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose.) and incubated further at 
37°C for 60 minutes. 
200 µl of those incubated cells were transferred onto “pre-dried” ampicillin plates 
which contained LB agar (100 µg/ml), where glass beads were utilised to ensure that the 
solution was spread across the entire plate. These loaded plates were left to incubate 
over night for approximately 17 hours at 37°C upside down, to enable sufficient growth. 
Following incubation, the transformation samples were purified using the QIAprep® 
Spin Miniprep Kit. They were later digested for an hour at a temperature of 37°C using 
the same procedure as previously stated in 2.2.14 using the restriction enzymes, XbaI 
and HidIII.  
To show the successful samples, a final electrophoresis gel was run for 40 minutes at 70 
w/v which compared the uncut DNA against the digested DNA. Prior to the making the 
gel, the uncut DNA had been diluted using 9µl of prepared T10E1 to 1µl of the sample, 
this ensured that the bands did not appear too bright on the gel and reduced the chance 
of smearing.  
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3.0 Results  
3.1 Strategy One 
3.1.1 Primer Design 
 
To complete the PCR- based site directed mutagenesis, primers were specifically 
constructed for successful laboratory research. Throughout the creating process 
numerous factors were involved including, the final annealing temperature and melting 
temperature, the G/C content, the primer sequence length and the number of di-
nucleotide repeats. Strategy steps 1 and 2 were effectively completed. The physical 
properties and template-binding sites of the primers are displayed in Table 3-1. 
Table 3-1. Initial Primer Design 
    Primer Nucleotide 
Sequence 
(5’- 3’) 
Annealing 
Temperatu
re (oC) 
Amino 
Acid 
Change 
Source Design 
pcDNA3F CCACTGCTTACTG
GCTTATCG 
65.3  Eurofins C.D*/ 
W-J.L** 
pcDNA3R GCCCTCTAGACT
CGAGCG 
66.3  Eurofins C.D*/ 
W-JL** 
VTC1P190SF GTCACCCCCACT
GTCTCC 
66.3 Proline to 
Serine 
Eurofins CD*/ 
W-J.L** 
VTC1P190SR GGAGACAGTGGG
GGTGAC 
66.3  Eurofins CD*/ 
W-J.L** 
VTC1V62GF ACCATCGCCGTG
CCCTTC 
66.3 Valine to 
Glycine 
Eurofins CD*/ 
W-J.L** 
VTC1V62GR GAAGGGCACGGC
GATGGT 
66.3  Eurofins CD*/ 
W-J.L** 
VTC1I96LF ACCACTCTCATCC
AGACCAC 
65.3 Isoleucine 
to 
Leucine 
Eurofins CD*/ 
W-J.L** 
VTC1I96LR ACCACTCTCATCC
AGACCAC 
65.3  Eurofins CD*/ 
W-J.L** 
VTC1L277FF ACAGACGTGCTG
CCCACAG 
66.3 Leucine 
to Valine 
Eurofins CD*/ 
W-J.L** 
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VTC1L277FR CTGTGGGCAG
CACGTCTGT 
66.3  Eurofins CD*/ W-
J.L** 
VTC1N385SF GTCCAGTCCC
AACATTGGC 
64.7 Asparagine 
to Serine 
Eurofins CD*/ W-
J.L** 
VTC1N385SR GCCAATGTTG
GGACTGGAC 
64.7  Eurofins CD*/ W-
J.L** 
VTC2A174VF CATTTTTGGCC
CCTGCTCGA 
65.3 Alanine to 
Valine 
Eurofins CD*/ W-
J.L** 
VTC2A174VR TCGAGCAGGG
GCCAAAAATG 
65.3  Eurofins CD*/ W-
J.L** 
VTC2K184RF TCTTTAGATAA
ATGGAAATGT
AACAC 
66.3 Lysine to 
Arginine 
Eurofins CD*/ W-
J.L** 
VTC2K184RF GTGTTACATTT
CCATTTATCTA
AAGACAGG 
66.3  Eurofins CD*/ W-
J.L** 
VTC2Q353GF GATGCCAGGC
AAGGCGTG 
66.3 Glutamine to 
Arginine 
Eurofins CD*/ W-
J.L** 
VTC2Q353GR CACGCCTTGCC
TGGCATC 
66.3  Eurofins CD*/ W-
J.L** 
VTC2D133GF GTGGGGTACG
ACCAGTGG 
66.3 Aspartic 
Acid to 
Glycine 
Eurofins CD*/ W-
J.L** 
VTC2D133GR CCACTGGTCGT
ACCCCAC 
66.3  Eurofins CD*/ W-
J.L** 
VTC2I381LF CCGGTGTCATC
GGCATGC 
66.3 Isoleucine to 
Leucine 
Eurofins CD*/ W-
J.L** 
VTC2I381LR GCATGCCGAT
GACACCGG 
66.3  Eurofins CD*/ W-
J.L** 
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Table 3-2. Dilutions, concentrations and purity of hSVCT1 and hSVCT2 
Plasmid Dilution Ratio 
Water (µl): 
DNA (µl) 
Concentration 
(ug/ ml) 
 
OD260 Reading 
(Concentration of 
nucleic acid) 
A260/280 
(Purity 
ratio) 
 
hSVCT1 
(1) 
3:1 17.3 0.345 1.81 
hSVCT1 
(2) 
2:1 29.3 0.587 1.86 
hSVCT2 
(1) 
5:1 20.7 0.414 1.86 
hSVCT2 
(2) 
3:1 21.4 0.429 1.89 
 
 
SVCT1 SVCT2 
1 kb 
Ladder 
Figure 3-1 Agarose gel electrophoresis of SVCT1 and SVCT2 after using the 
QIAprep@ Spin Miniprep Kit. The agarose gel shows successful miniprep of the 
samples, hSVCT1 and hSVCT2, which illustrate supercoiled DNA. The bright 
staining of the bands suggest too much DNA is in the samples however this is 
expected following using the miniprep kit. The image was taken on a Bio-Rad 
ChemiDocTM MP imaging system with the use of UV light. Samples were used for 
both strategy one and strategy two. The method and reagents utilised are stated in 
2.2.7 and the volumes of reagents, primers and their sources are described in 
Materials 2.0. 
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3.1.2 Extraction of Plasmids phSVCT1 and phSVCT2 
Prior to completing PCR, the concentrations of the plasmids SVCT1 and SVCT2 were 
measured using the DNA Nanodrop. It was crucial to ensure that the current 
concentrations were close to a value of 50ng/ul as this would alter the volumes of 
plasmid added during PCR. Furthermore, the optical density at 250nm was required to 
be between 0.2-0.8 and the OD260/0D280 ratio was between 1.8-2.0. Certain dilutions 
were made to the samples using distilled water until the necessary values were within 
the range. See Table 3-2 for the results of the plasmid concentrations. 
Stage 3 was positively completed. The plasmids phSVCT1 and phSVCT2 were 
successfully extracted and purified from the E.coli DH5α cells, in preparation to be 
utilised as both parent clones and vectors. Figure 3-1 shows the TAE agarose 
electrophoresis gel results for the following the inoculation of SVCT1 and SVCT2 after 
miniprep. The use of the QIAprep® Spin Miniprep Kit was efficient allowing 
approximately 8µg of plasmid DNA taken from each innoculon. 
3.1.3 First Step Polymerase Chain Reaction of human SVCT1 and 
human SVCT2 samples. 
Step 4 was successful on the first attempt as displayed in Figure 3-2 and Figure 3-3. The 
constructed primers and chosen PCR settings were beneficial for the amplification of 
the overlapping hSVCT fragments, this allowed ~2µg of desired product to be taken 
from each plasmid template. Purification was effective and consequently there was 
approximately 5ng/µl of required PCR product within each 50µl sample. Bands 2 and 5 
in Figure 3-2 are both faint in the image however they were visible by the human eye 
following completion of the gel electrophoresis. The two bands matched the predicted 
sizes in comparison to the 1kb ladder and consequently these samples were used during 
the next stage of the process along with the other successful samples.  
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1kb 
Ladder 
VtC1- 
I96L 
(F) 
VtC1- 
I96L 
(R) 
VtC1- 
V62G 
(F) 
VtC1- 
V62G 
(R) 
VtC1- 
L277F 
(F) 
VtC1- 
L277F 
(R) 
VtC1- 
P190S 
(F) 
VtC1- 
P190S 
(R) 
VtC1- 
N385S 
(F) 
VtC1- 
N385S 
(R) 
3-2 Agarose gel electrophoresis of the first attempt at primary PCR for 
hSVCT1 samples. The image shows that the gel electrophoresis was successful for 
all samples, excluding one. The bands display bright staining on the gel which 
would indicate too much DNA in the samples. All successful samples are located at 
the correct weights based on their sequence lengths. The image was taken on a Bio-
Rad ChemiDocTM MP imaging system with the use of UV light. The method and 
reagents utilised are stated in 2.2.8 and the volumes of reagents, primers and their 
sources are described in Materials 2.0. 
1kb 
Ladder 
VtC2- 
I138L 
(F) 
 
VtC2- 
I138L 
(R) 
 
VtC2- 
D133G 
(F) 
 
VtC2- 
D133G 
(R) 
 
VtC2- 
K184R 
(F) 
 
VtC2- 
K184R 
(R) 
 
VtC2- 
A174V 
(F) 
 
VtC2- 
A174V 
(R) 
 
VtC2- 
Q353G 
(F) 
 
VtC2- 
Q353G 
(R) 
 
3-3 Agarose gel electrophoresis of the hSVCT2 samples from the first attempt 
at primary PCR. The image shows that primary PCR was successful for all 
samples as the bands are located in the correct position in relation to the 1kb 
ladder, for their expected weight. All band staining is too bright which suggest too 
much DNA in the samples. The image was taken on a Bio-Rad ChemiDocTM MP 
imaging system with the use of UV light. The method and reagents utilised are 
stated in 2.2.8 and the volumes of reagents, primers and their sources are described 
in Materials 2.0. 
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3.1.4 Fusion Polymerase Chain Reaction 
Strategy step 5 was completed successfully using gradient PCR and is illustrated in 
Figure 3-4. All of the first step PCR products were fused with the corresponding 
remaining overlapping fragments to result in a total of 10 fused products. Five fusion 
products were formed for hSVCT1 and another five for hSVCT2. The results in Figure 
3-4 are following multiple attempts to reach successful fusions at the correct sizes. The 
bands were then extracted from the gel using the QIA gel extraction kit to remove any 
unwanted DNA or impurities from the samples which may obstruct the next stage. 
3.1.5 Plasmid and Fusion Product Restriction Digest using XbaI and 
HindIII.  
 
Step 6 was the double digestion using HindIII and XbaI simultaneously, in addition to 
the plasmids phSVCT1 and phSVCT2 DNA. The plasmid restriction digest was 
successful on the first attempt as shown in Figure 3-5. This would have allowed the 
plasmid DNA to be linearized, forming overhanging ends that were complementary to 
1kb 
Ladder 
VtC1
P190S 
VtC1
V62G 
VtC1I
96L 
VtC1
L277
F 
VtC1
N385
S 
VtC2
A174
V 
VtC2
K184
R 
VtC2
Q353
G 
VtC2
D133
G 
VtC2I
381L 
Figure 3-4 Agarose gel electrophoresis of fusion PCR products. The gel electrophoresis 
was run using Bio-Rad 1-D gel electrophoresis equipment at 70V for 50 minutes, 4ul of the 
DNA sample was loaded into the 1.5% gel. The bands for each sample are at approximately 
2kb which is accurate corresponding with their predicted sizes. The method and reagents 
utilised are stated in 2.2.12 and the volumes of reagents, primers and their sources 
are described in Materials 2.0. 
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those which were formed during the previous stage. However, the restriction digest of 
the DNA samples was unsuccessful following multiple attempts, see Figure 3-6. 
Multiple troubleshoots were attempted for restriction digest of the DNA samples 
including altering the DNA concentration, volume loaded into the wells, gel 
electrophoresis running times, restriction enzyme volumes and BSA volume. 
Nevertheless, all electrophoresis gels appeared blank with no bands visible to the human 
eye or via the Bio-Rad ChemiDocTM MP imaging system. Therefore, it was evident that 
the concentrations and purity of the samples needed to be checked to ensure that a 
viable volume of DNA was in the sample. The Nanodrop results are shown in the Table 
3-3 which indicate the concentration of required DNA is minimal. 
 
 
 
1kb 
Ladder 
SVCT1 SVCT1 SVCT1 SVCT2 SVCT2 SVCT2 
Figure 3-5 Restriction digest of the plasmids SVCT1 and SVCT2. Restriction 
digest of the two SVCT plasmids using the restriction enzymes XbaI and HindIII. 
The gel electrophoresis was run using Bio-Rad 1-D gel electrophoresis equipment at 
70V for one hour, 8ul of the DNA sample was loaded into the 1.5% gel. Apparent 
restriction fragment lengths shown by the bands are as expected for phSVCT1 and 
phSVCT2. 
48 
 
 
Table 3-3. Concentrations and purity of samples following restriction digest. 
Sample Concentration 
(ng/ul) 
OD260 Reading 
(Concentration of 
nucleic acid) 
A260/280 
(Purity Ratio) 
VtC1V62G 21.6 0.433 0.63 
VtC1I96L 26.3 0.525 0.68 
VtC1IL277F 10.0 0.200 0.65 
VtC2A174V 6.5 0.130 0.53 
VtC2K184R 27.2 0.543 0.62 
VtC2D133G 18.8 0.542 0.11 
 
The Nanodrop results show that although the overall concentration of the samples is 
good, the required DNA purity is very low suggesting that the samples may be 
contaminated, or the DNA has been lost during previous stages. Consequently, it was 
apparent that using these samples would provide unsuccessful results and it would be 
beneficial to begin the laboratory process from the beginning.  
1kb 
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VtC1
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VtC
1V6
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VtC
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VtC
1I96
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VtC1
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VtC2
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V 
VtC2
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V 
VtC2
K184
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VtC
2K1
VtC2
D133
G 
VtC2
D133
G 
Figure 3-6 Agarose gel electrophoresis of restriction digest products. Agarose 
gel electrophoresis of the digested samples using the restriction enzymes HindIII 
and XBaI which are incubated for 4 hours. It is evident that the restriction digest 
was not successful for any of the samples, no bands are visible to the human eye 
or via the image. The image was taken on a Bio-Rad ChemiDocTM MP imaging 
system with the use of UV light. The method and reagents utilised are stated in 
2.2.14 and the volumes of reagents, primers and their sources are described in 
Materials 2.0. 
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3.2 Strategy Two 
3.2.1 Primer Design 
 
To make the improved strategy successful, slight alterations were made to the primer 
sequences. These improvements included alterations to the sequence lengths, G/C 
content and amino acid changes. These improvements were made to increase the 
effectivity of the project and to increase the possibility of changes to the transport 
functions of SVCT. 
1 and SVCT2. Strategy steps 1 and 2 were effectively completed and primer designs are 
displayed in the Table 3-4. 
 
     Table 3-4. Revisited Primer Design 
Primer Nucleotide 
Sequence 
(5’-3’) 
GC- 
Content 
% 
Annealing 
Temperature 
(oC) 
Amino 
Acid 
Change 
Source Design 
pcDNA
3F 
CCACTGCT
TACTGGCT
TATCG 
 65.3  Eurofins C.D*/ W-
J.L** 
pcDNA
3R 
GCCCTCTA
GACTCGA
GCG 
 66.3  Eurofins C.D*/ W-
JL** 
mVC1
P190SF 
GTCACCT
CCACTGT
CTCC 
61.1 58.2 Alanine to 
Valine 
Eurofins C.D*/ W-
J.L** 
mVC1
P190S
R 
GGAGACA
GTGGAGG
TGAC 
61.1 58.2  Eurofins C.D*/ W-
J.L** 
mVC1
L277E
F 
ACAGACG
TGCAGCC
CAC 
63.2 61.0 Leucine to 
Valine 
Eurofins C.D*/ W-
J.L** 
mVC1
L277E
R 
CTGTGGG
CTGCACG
TCTGT 
63.2 61.0  Eurofins C.D*/ W-
J.L** 
50 
 
mVC1
N385S
F 
GTCCAGT
CCCAGCA
TTGGC 
63.2 61.0 Asparagine 
to Serine 
Eurofins C.D*/ W-
J.L** 
mVC1
N385S
R 
GCCAATG
CTGGGAC
TGGAC 
63.2 61.0  Eurofins C.D*/ W-
J.L** 
mVC2
K184E
F 
CCTGTCT
TTAGATG
AATGGAA
ATGTAAC
AC 
36.7 62.7 Lysine to 
Arginine 
Eurofins C.D*/ W-
J.L** 
mVC2
K184E
R 
GTGTTAC
ATTTCCA
TTCATCT
AAAGACA
GG 
36.7 62.7  Eurofins C.D*/ W-
J.L** 
mVC2
Q353G
F 
GATGCCA
GGCGAGG
CGTG 
72.2 62.8 Glutamine 
to Arginine 
Eurofins C.D*/ W-
J.L** 
mVC2
Q353G
R 
CACGCCT
CGCCTGG
CATC 
72.2 62.8  Eurofins C.D*/ W-
J.L** 
mVC2
D133G
F 
GTGGGGT
ACGGCCA
GTGG 
72.2 62.8 Aspartic 
Acid to 
Glycine 
Eurofins C.D*/ W-
J.L** 
mVC2
D133G
R 
CCAACTG
GCCGTAC
CCCAC 
72.2 62.8  Eurofins C.D*/ W-
J.L** 
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3.2.2 Extraction of Plasmids phSVCT1 and phSVCT2 
 
Stage 3 was successful. Extraction of plasmids phSVCT1 and phSVCT2 were taken 
from Strategy 1. These had previously been inoculated and were extracted using the 
QIAprep® Spin Miniprep Kit. The TAE gel electrophoresis results are shown in Figure 
3-1. 
3.2.3 Primary PCR of hSVCT1 and hSVCT2 samples 
 
Stages four and five, primary PCR and Dpn1 treatment were successful. The annealing 
temperature and programme setting were designed based on the style of PCR being 
utilised and the primers. This form of PCR does not include the use of flanking primers 
and only the mutated primers and plasmids. Consequently, the programme settings are 
lengthened to allow enough time for the PCR to work. Dpn1 treatment was successfully 
completed to ensure the majority of methylated DNA was removed.  
3.2.4 Transformation 
 
Stage six, transformation appeared successful. The transformation procedure was first 
optimised using a positive control (undigested hSVCT1 and hSVCT2 vectors) which 
gave rise to many colonies as predicted. This indicated that the transformation 
procedure was relatively reliable and that any colony growth on the plates would be 
successful transformation of the mutants.  Transformation of the mutated samples into 
competent JM109 E.coli appeared successful for three of samples. Transformation of 
samples mVC1P190S, mVC1L277E and mVC2D133G were unsuccessful with no 
colonies formed (Figure 3-7). Transformation for samples mVC1N385S, mVC2K184E 
and mVC2Q353G formed colonies following overnight incubation at 37 oC. Sample 
mVC1N385 formed 5 visible colonies, mVC2K184E shows 3 visible colonies and 
mVC2Q353G formed 7 colonies (Figure 3-8). Although these appeared successful the 
transformation efficiency is lower than expected for the amount of DNA which was 
added. Following this transformation procedure, it was expected that each sample would 
arise to 10-15 colonies forming on each plate, therefore these results were lower than 
predicted.  
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Figure 3-7. Attempted Transformation of Competent E.coli with mutated samples. The 
transformation procedure is stated in Methods. The photographs were taken using a light 
box with a f/5.6 for 3 seconds. No colonies formed for mVC1P190S, mVC1L277E and 
mVC2D133G following overnight incubation at 37 oC.  
Figure 3-8. Attempted Transformation of Competent E.coli with mutated samples. 
The transformation procedure is stated in Methods. The samples mVC1N385S, 
mVC2K184E and mVC2Q353G formed colonies following overnight incubation at 37 
oC. mVC1N385 formed 5 visible colonies, mVC2K184E 3 visible colonies and 
mVC2Q353G formed 7 colonies. The photographs were taken using a light box (to 
visualise the colonies clearly) with a f/5.6 for 3 seconds. 
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3.2.5 MiniPrep and Restriction Digest using XbaI and HindIII. 
Step seven was effective with the use of the QIAprep® Spin Miniprep Kit following the 
protocol stated in the Methods. A total of five colonies were chosen from the successful 
samples; two for mVC1N385S, two for mVC2Q353G and one chosen from 
mVC2K184E. For each colony two sets of miniprep was completed in case of any 
errors occurring during the procedure, this would ensure that the samples can be 
successfully sequenced. Following successful miniprep and prior to the samples being 
sequenced a restriction digest was completed using the restriction enzymes XbaI and 
HindIII. The restriction digest protocol is stated in the Methods and both samples were 
left for 4 hours to be incubated at 37 oC. The results in Figure 3-9 shows the cut and the 
uncut versions of each sample to compare whether the DNA is supercoiled, nicked or 
linear.  
 
 
 
 
 
 
 
3.2.6 Sequencing  
The samples were analysed at an external company to confirm that there is a successful 
mutation within the sequences. The results showed that the sequencing reactions were 
all effective therefore suggesting that the DNA was clean. Nevertheless, the intended 
mutagenesis was not successful at the targeted sites and the samples being analysed 
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Figure 3-9. Gel Electrophoresis results after restriction digest using XbaI and HindIII. 
The restriction digest procedure and protocol are stated in the Methods 2.1.14. The gel 
electrophoresis was run using Bio-Rad 1-D gel electrophoresis equipment at 70V for one 
hour, 4ul of the DNA sample was loaded into the 1.5% gel. Apparent restriction fragment 
lengths shown by the bands are as expected between the cut and the uncut DNA. 
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were very similar to the original hSVCT1 and hSVCT2 sequences. However, certain 
mutations are present in the samples which had not been predicted or planned that are 
likely to have occurred during the PCR procedure. Figures 3-10, Figure 3-11, Figure 3-
12 and Figure 3-13 indicate where these mutations are located using pairwise sequence 
alignment, EMBOSS Needle of the nucleotide sequences. These mutations are stated in 
comparison to the original hSVCT1 and hSVCT2 published sequences. Unintended 
mutations have been located in the following sequences; mVC1N385S (1), 
mVC1N385S (2), mVC2K184E (1) and mVC2K184E (2). 
Figure 3-10. Results of the pairwise alignment of the resultant mVC1N385S (1) and (2) 
sequences with the published hSVCT1 sequence and Chromas results. The pairwise 
alignment was calculated using the EMBOSS Needle tool which calculated the optimal 
global alignment of the two sequences. The pairwise alignment settings were fixed to gap 
open penalty-10, gap extension penalty- 0.5, the Matrix as DNAFull and the output format 
as ‘pair’. The results show that there is high similarity between the sequences and an 
unintended mutation from AGT (Serine) to AAT (Asparagine).  Chromas 2.6.4 software was 
utilised to analyse the sequence and confirm that this mutation was present.  
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Figure 3-11. Results of the pairwise alignment of the resultant mVC1N385S (2) 
sequence with the published hSVCT1 sequence and Chromas results. The pairwise 
alignment was calculated using the EMBOSS Needle tool which calculated the optimal 
global alignment of the two sequences. The pairwise alignment settings were fixed to gap 
open penalty-10, gap extension penalty- 0.5, the Matrix as DNAFull and the output format 
as ‘pair’. The results show that there is high similarity between the sequences and an 
unintended mutation from GGC (Alanine) to GCA (Glycine). Chromas 2.6.4 software was 
utilised to analyse the sequence and confirm that this mutation was present. 
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Figure 3-12. Results of the pairwise alignment of the resultant mVC1N385S (2) 
sequence with the published hSVCT1 sequence and Chromas results. The pairwise 
alignment was calculated using the EMBOSS Needle tool which calculated the optimal 
global alignment of the two sequences. The pairwise alignment settings were fixed to gap 
open penalty-10, gap extension penalty- 0.5, the Matrix as DNAFull and the output format 
as ‘pair’. The results show that there is high similarity between the sequences and an 
unintended mutation from TCA (Serine) to TTC (Phenylalanine). Chromas 2.6.4 software 
was utilised to analyse the sequence and confirm that this mutation was present. 
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Figure 3-13. Results of the pairwise alignment of the resultant mVC2K184E (1) and (2) 
sequences with the published hSVCT1 sequence and Chromas results. The pairwise 
alignment was calculated using the EMBOSS Needle tool which calculated the optimal 
global alignment of the two sequences. The pairwise alignment settings were fixed to gap 
open penalty-10, gap extension penalty- 0.5, the Matrix as DNAFull and the output format 
as ‘pair’. The results show that there is high similarity between the sequences and an 
unintended mutation from CTG (Leucine) to ATG (Methionine). Chromas 2.6.4 software 
was utilised to analyse the sequence and confirm that this mutation was present. 
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4.0 Discussion 
4.1 Discussion of Results  
 
The purpose of this research masters was to complete site-directed mutagenesis by 
specifically altering sites on the protein sequences of the two human vitamin C 
transporters. This would purposely create mutations in the sequences which 
consequently modifies the coding genes. The sites were chosen due to two factors; their 
location on the sequence and the structure of the amino acid acting as the mutation. The 
site of the point mutation could potentially be crucial for the transporter functionality 
and potential mechanisms that regulate its activity (Inoue, 2017). Studies on the SVCT1 
and SVCT2 structure and function have taken place for the last decade, however 
minimal knowledge is known on how these proteins will react to new substances 
entering the human body. Across the medical and pharmaceutical industry new 
medicines are regularly and rapidly being designed and although they are thoroughly 
tested, little understanding is known on how they will influence the two vitamin C 
transporters (Jacobs et al., 2015). This knowledge could be vital for individual’s health, 
particularly those who are at risk of low ascorbate levels and could be beneficial during 
the design of new medicines (Schlueter and Johnston, 2011). 
The strategy and planning of this research was scheduled prior to any laboratory work 
commenced, this included a Gantt chart which reviewed the stages which should be 
accomplished per month. The majority of the objectives for this project were all met 
within the time frame across the 11-month period. The successful objectives were 
achieved with numerous troubleshoots to try and attain the ultimate results and 
successful clones. This included external sequencing and bioinformatic sequencing to 
test whether the mutated samples were grown into the original plasmid (Brown et al., 
2014). The strategy was altered mid-way through the research with an improved and 
shorter method to make it more efficient due to time factors. Due to this change certain, 
stages were removed that had previously been completed but were unsuccessful 
including; fusion PCR, restriction digest and ligation.  
4.2 Major Findings 
1) Primers were successfully designed based upon the amino acid location on the primary 
structure of the transporters with the use of bioinformatics tools to check the protein and 
59 
 
nucleotide sequences. The mutations of the designed primers were also based on the 
varying amino acid structures.   
 
2) The primary PCR was successful for all mutants using both the original and improved 
method.  
4.3 Implications of the Results 
 
The initial growth of the SVCT strains (provided by WJ Liang, Liang et al 2001; 2002) 
were effective and provided constituents needed for PCR that were correctly diluted. 
The E. coli strains DHα (phSVCT1) and DHα (phSVCT2) both hold a B-lactamase gene 
on their plasmids, which enables their selection and recovery in LB ampicillin media 
(Larsson et al., 2015). The two plasmids were extracted successfully, and the gel 
electrophoresis showed the DNA to be located at ~8-10kb.  
Understanding the formations of circular DNA is essential; 3 conformations exist, 
supercoiled, open-circular and linear. Within the laboratory, on completion of precise 
plasmid preparation, most DNA is formatted as supercoiled however a number will 
tolerate single strand nicks, where they are in a relaxed conformation (Smith 1996). It is 
known that supercoiled DNA runs faster during gel electrophoresis through the gel 
matrix in comparison to linear DNA (Bendel and James 1983). This knowledge was 
consequently crucial when analysing the electrophoresis gels after they had been run, to 
understand the format of the DNA.  
For plasmid extraction the DNA showed to have two topological forms as two bands 
appeared on the gel as shown in Figure 3-1. These were nicked and relaxed which is 
expected for plasmids which have been extracted from the bacterial cell. Primary PCR 
was successful for each strategy with bands located at the correct weight. The 
programme for PCR was designed based upon the annealing temperatures of the 
primers which on average was 61.0oC.  This temperature appeared to provide optimal 
conditions for successful PCR and reduced the chances of non-specific binding. 
GoTaq® Flexi DNA Polymerase and MgCl2 were used during all PCR reactions which 
improved and amplified the templates considerably as they both have a large influence 
on primer hybridization and enzyme fidelity. To confirm the results of PCR, gel 
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electrophoresis was completed and the band weights were between ~0.5 and ~1kb 
which is expected for these amplicons. 
Fusion PCR was successful during the first strategy of this research following several 
attempts, all bands were located at the correct weight in comparison to the 1kb ladder. 
The programme initially utilised the identical primary PCR programme. However, after 
an unsuccessful first attempt the programme was altered to reduce the annealing 
temperature to 60.0 oC. This gave another negative result where no bands appeared on 
the electrophoresis gel. The second troubleshoot doubled the volume of template DNA 
from 2ul to 4ul which resulted in visible bands however at this stage they were too 
bright and certain bands emerged at the incorrect size. From these results it appeared 
beneficial to analyse the samples using the nanodrop to check the concentrations. The 
samples were measured and diluted accordingly so that each sample had approximately 
5ng of the required DNA. Following the corrected dilutions to these samples the fusion 
was successful for all 10 mutants. In addition to the QIA Purification Kit a technique 
involving the use of sepharose and Cl-6B to filter through the sample. The results 
represented the efficiency of this method which is improved and more effective than the 
QIA Purification Kit.  
For restriction digest the enzymes XbaI and HindIII were chosen as they appeared to be 
the most suitable for cleaving the restriction sites and producing highly reactive ‘sticky 
ends’. Both enzymes have similar reaction kinetics allowing them both to be involved in 
the digest reaction at the same time with similar incubation conditions. The restriction 
digest was successful on the first attempt for the diluted plasmids SVCT1 and SVCT2, 
which were consequently extracted using the QIA gel extraction kit. Attempts at 
restriction digest on the purified fusion products were unsuccessful following three 
troubleshoots. The first troubleshoot involved doubling the volume of DNA sample 
from 5ul to 10ul and incubating the samples at 37°C for 4 hours. To complete the 
agarose gel 4ul of the sample was loaded into the wells however the results showed no 
bands appearing on the gel. For the second troubleshoot the same constituents and 
volumes were used however new batches of the enzymes and NEB Buffer 2 were 
ordered to ensure that no contamination was occurring. This presented the same results 
as previously where no bands appeared on the gel following 4ul of DNA being loaded 
into the wells. The final troubleshoots used 10ul of DNA sample to be digested however 
for the gel electrophoresis 8ul of the sample was loaded, to increase the chances of a 
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visible band with the correct weight. This final attempt was also not successful 
suggesting that an insufficient amount of DNA was in the samples.  
Another limitation became apparent after the incompletion of restriction digest, 
throughout the process all electrophoresis gels were prepared at 1.5%. Due to the sizes 
of the predicted bands being between 1-7kb long it would have been beneficial to 
prepare the electrophoresis gels with a concentration of agarose at 0.8%. This would 
have increased the resolution and resulted in a greater separation between bands of a 
similar size. This factor could have consequently affected whether bands appeared on 
the gel following restriction digest.  Due to this unsuccessful stage, the DNA sample 
concentrations were checked using the Nanodrop which confirmed that low 
concentrations of the required DNA were present in these samples. It is unclear if these 
were lost during the extraction process or if other factors such as the quality of the 
restriction enzymes affected the result. 
The Table 3-3 shows the Nanodrop results following the final attempt at restriction 
digest. The results show that the OD A260 readings, which is a quantity measure for 
nucleic acids, are within the expected values as they fall between 0.2 and 0.8. The 
260/280 ratio provided the explanation why the restriction digest was not successful. 
The ratio should be between 1.8-2.0 therefore these results are considerably low to what 
was expected. As the 260/280 ratio measures the purity of the samples, it suggests that 
little pure DNA was in the samples and that high levels of contaminants are present. 
 Due to these results a new strategy was designed to allow the research to be completed 
during the time frame and to achieve the growth of mutated hSVCT1 and hSVCT2 
sequences. A new form of PCR was researched and used during this strategy of the 
project. ‘Round-the-horn’ PCR for site-specific mutagenesis was used where both 
primers contain the mutations and they are phosphorylated so that the PCR products can 
be ligated into a circle. This technique only requires small primers and if a band appears 
during gel electrophoresis it indicates that the reaction was successful and they must 
contain the mutations. The procedure is effective as it rapidly amplifies the plasmid 
which causes increases in yield and transformation efficiency. 
To successfully complete the revisited primary PCR no flanking primers were involved, 
only the plasmid and the mutant forward and reverse primers. The volumes and 
constituents of primary PCR were altered and therefore the programme was also 
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adapted. The new programme ran for approximately six hours and the following settings 
were utilised; heat the lid to 100°C , 95°C for 5 mins, then 30x cycles each at 94°C for 1 
min ,an extension of 61°C for 30 seconds, 72°C for 10 mins and a final extension at 
72°C for 4 mins. The annealing temperature was adjusted to 61.0oC as this was the 
average temperature of all six samples, this provided optimum conditions thereby 
increasing the efficiency of the PCR reaction. Following primary PCR and Dpn1 
treatment, the new strategy was utilised with transformation and growth of the 
mutations into the plasmid as the next step. 
Transformation for human SVCT containing plasmids into competent E.coli appeared 
successful for three out of the six samples. To provide good experimental data, the 
positive controls, SVCT1 and SVCT2 plasmids were plated. The results were as 
predicted with an abundance of colonies growing, confirming the competency of the 
transformation procedure. Overall only 1-10 tranformants grew per plate which is fewer 
than predicted, this could be linked to several factors. One limitation suggests that an 
insufficient number of cells were plated and therefore the volume of cells would need to 
be adjusted to obtain a desirable number of colonies. It would have also been beneficial 
to pre-warm the medium and plates, to increase the probability of colony growth. The 
final factor that may have altered the transformation efficiency was the amount of DNA 
used, for 1-10ng of DNA approximately 50-100ul of competent cells should be utilised. 
A suitable selection of colonies grew onto the LB plates for samples mVC1N385S and 
mVC2Q353G and two individual growths were selected, depending on their size and 
distribution on the plate. Sample mVC2K184E had only three visible colonies on the 
plate, therefore, only one colony was chosen to be sequenced.  
Following the inoculation of each colony into LB media, the samples successfully 
underwent miniprep using the QIAMiniPrep kit and were stored in the freezer. To 
confirm the success of the results a restriction digest took place to compare the cut and 
uncut samples. The digest confirmed the apparent successful growth of the clones and 
confirmed the transformation efficiency as the DNA appeared supercoiled. The samples 
were sent to an external sequencing company to analyse the samples and test them 
within mammalian cells.  
Changes in DNA associated with mutation can lead to errors in the protein sequences 
and creating non-functional protein. To function optimally, each amino acid and its 
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location is crucial for a protein to work (Choi and Chan, 2015). When a mutation 
cooccurs it can alter the functioning of the transporter proteins, thereby affecting the 
whole human body. The concluding results for each sample showed that all sequencing 
reactions were functioning suggesting that the mutagenesis methodology was completed 
effectively and efficiently and therefore the DNA was clean. This result also confirms 
that the designed and revisited strategy was successful and that it can be applied to other 
scientific research in the future. However, the intended mutagenesis was not successful 
at the targeted sites and therefore the sequences are highly similar to hSVCT1 and 
hSVCT2. The cause for the mutagenesis to be unsuccessful will have likely occurred 
during the PCR process where the forward and reverse primers did not meet. 
Furthermore, it is unclear how effective the Dpn1 treatment was during this procedure 
and consequently not all methylated DNA will have been digested.  
The sequencing results indicated that the samples had additional mutations which were 
not intended. These mutations were predominantly found in samples mVC1N385S (1) 
and (2) and one mutation found in mVC2K184E. Although these substitutions were not 
intentional they may still affect the transport functionality and ability of the two vitamin 
C transporters (Kitzman et al., 2017).  The first located point mutation is shown in 
Figure 3-10 which substitutes Serine to Asparagine. Both amino acids are fairly small in 
size, polar and are non-essential to humans as they can be naturally synthesised. Due to 
their similar biochemical properties, particularly as they are both polar, it is likely this is 
a conservative mutation and therefore there would only be a small effect to the function 
of the hSVCT1 transporter.  
Figure 3-11 shows the mutation from Alanine to Glycine which occurs in the SVCT1 
transporter. These amino acids have similarities as they are classed as aliphatic and 
hydrophobic however their functions differ. Alanine is non-polar and has a side chain 
which is very non-reactive consequently it is not involved in protein function (Klatte 
and Wendish, 2015). Glycine holds a hydrogen on its side chain making it more flexible 
and likely to reside on protein structures playing a distinctive role in their functions. 
Therefore, there is a possibility that this mutation in the hSVCT1 transporter may 
improve or reduce the transport activity of the protein. Figure 3-12 shows the mutation 
in SVCT1 from Serine to Phenylalanine. Serine is small in size, polar and classed as 
hydroxyl where Phenylalanine is classed as aromatic and hydrophobic (Wu, 2009). 
Similarly, both amino acids are fairly non-reactive and have side chains which do not 
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affect protein functioning, although Phenylalanine can be involved with substrate 
recognition.  
The final mutation was found in sample mVC2K184E and is shown in Figure 3-13 and 
indicates that Leucine has changed to Methionine. Both amino acids are stated as 
hydrophobic,  where Leucine is classed as aliphatic. The structure, size and biochemical 
properties are all very similar between these amino acids and therefore it is unlikely that 
the SVCT2 transporter function would be altered or reduced (Hansen et al., 2017).  
Mutagenesis of the desired targets were unsuccessful, however after evaluating the 
sequences it is evident that certain mutations, between Alanine and Glycine, may 
influence the protein transport activity. Certain artificial molecules were also produced 
during the PCR reaction, which may have been caused by too many cycles in the PCR 
programme (Wu, 2009). The cause of the mutations during this research is unclear 
however one factor includes undesired reactions between different template molecules 
(Miyazawa, 2013). The insert of mutations to the final samples may also be linked to 
the DNA polymerase used during PCR which needs to be high fidelity. Finally, the 
quality of the dNTP’s can occasionally lead to mutations in sequences, where they have 
been stored incorrectly or used at inappropriate concentrations.   
4.4 Significance of the Research in the Field 
 
The functioning sequencing reactions of the samples suggest that the technique chosen 
of ‘Round-the-Horn’ PCR and transformation methods were effective and highlights the 
procedures flexibility and efficiency. Although the targeted mutations did not occur the 
unintended changes provide an opportunity for further research into whether these 
amino acid substitutions will affect the efficiency and functionality of the transporters, 
when studied on mammalian cells. 
Modifications in expression or functionality of SVCT1 and SVCT2 have not yet been 
associated with human disease, and no substances have been linked to influence either 
of the two transporters in the clinical environment (Wohlrab, Phillips and Dachs, 2017). 
However, the importance of the transporters for sustaining cellular ascorbate 
concentrations and the importance of vitamin C for human health is evident (Gaziano et 
al., 2009; Stephenson et al., 2013). This research will also aid the design of new 
pharmaceutical drugs and medicines to ensure that they will not affect the two vitamin 
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C transporters. This will benefit those individuals whose overall health is influenced by 
low ascorbate levels or to those whose are using high levels of vitamin C to aid a 
specific condition (Yousef et al. 2012; Figueroa-Méndez and Rivas-Arancibia 2015). 
Further studies into whether these samples have influenced the transport activity of the 
proteins will provide a better understanding on how important vitamin C is for humans 
and other mammals who cannot naturally synthesise the micronutrient. In humans, who 
are unable to naturally synthesise ascorbic acid, a dysfunctional SVCT1 or SVCT2 can 
instigate a significant reduction of ascorbate and clinical consequences occur, 
particularly during pregnancy (Carr et al.,2014). Understanding the mechanisms and 
factors that regulate the uptake of vitamin C within humans can aid the design of 
therapeutic strategies for degenerative diseases, including cancer. 
4.5 Limitations of this Project 
 
The main limitations associated with this research project are linked to time constraints 
and availability of the required constituents. As there were only nine months available 
for the practical elements of this research each stage had to be completed by a certain 
date. This reduced the available time to complete as many troubleshoots needed to 
improve the quality of the results. This includes reducing smearing on electrophoresis 
gels, improved nanodrop results and repeating stages where necessary if no results were 
found for a particular sample. The initial background study, use of bioinformatic tools 
and design of strategy 1 was completed efficiently. However, unforeseen 
troubleshooting took up a substantial amount of time and supplies during this research 
leading to the first stages taking longer than expected. Following the unsuccessful 
restriction digest, the decision was made to design a new strategy that would be 
effective within the available time. This required further knowledge in relation to 
laboratory skills and understanding of the two transporter proteins. With the availability 
of more time strategy 2 could have been repeated numerous times until a successful 
clone was formed, thereby achieving all objectives of the project. Although time 
constraints were a factor throughout this research, the availability of laboratory 
equipment and most importantly the constituents, also moulded how productive the nine 
months were.  
During this study, all procedures were completed within the university laboratory which 
is shared between undergraduates, masters students and PhD students. Therefore, during 
66 
 
busy semesters certain equipment was not always readily available or faulty and 
practical work had to be delayed. Furthermore, resources including; GoTaq Polymerase, 
Dpn1 enzyme, dNTP, pipette tips and falcon tubes were used continually by many 
students and therefore rapidly ran out. Many components were not replaced and had to 
be ordered which used up valuable laboratory time. Without these products most of 
stages could not be completed and the research was further delayed. Building an 
effective strategy to complete site directed mutagenesis, whilst withstanding reliability 
and functionality of the two transporters, is a challenging and extensive procedure. 
During the early stages of the practical work, troubleshoots were positively conquered 
and these techniques were utilised at later phases during the study, nevertheless due to 
the number of obstacles occurring it was apparent that not enough time was available to 
complete the research. These troubleshoots in addition to complications with resources 
potentially hindered the project’s completion.  
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5.0 Conclusion and Further Work 
5.1 Conclusion 
The aim of this study was to complete site directed mutagenesis on the two human 
vitamin C transporter coding sequences, to highlight at a molecular level what governs 
their behaviour and functionality. Objectives 1 and 2 were achieved, with analysis of the 
coding sequences and designing of primers required for the laboratory procedures. 
Primary and secondary PCR were achieved, providing fusion products which contained 
the altered amino acid on each sequence. Objective three was not reached due to 
numerous troubleshoots being unsuccessful and the final transformation clones did not 
contain the intended mutations. Sequencing provided confirmation that the mutagenesis 
was not completed at these sites, however mutation at other regions on the sequences 
did take place. After analysing these changes and where they are located, it is evident 
that these substitutions could be beneficial in providing insights into the transport 
activities of hSVCT1 and hSVCT2 (Kocot and Luchowska-Kocot, 2017).  
These clones are consequently available to be identified and used for additional 
research, to test if there is any influence on the two transporter proteins. hSVCT1 and 
hSVCT2 are the primary carriers of vitamin C, which has been linked with supporting 
the prevention of numerous disorders and conditions. Due to numerous predictions from 
sequence analysis, inadequate amounts of experimental data and lack of knowledge 
concerning the molecular behaviour of human SVCT1 and human SVCT2, expression 
and additional valuation of these final samples could be significantly advantageous.  
5.2 Future Work 
Full completion of the objectives of this research project are highly feasible with the 
opportunity of more time for troubleshooting at each stage and optimisation of the 
conditions to make the laboratory procedures effective. It would be beneficial to 
increase the number of codons being modified on the sequences to highlight more 
regions which are important for the transporter functionality. Furthermore, it would be 
advantageous to complete site directed mutagenesis using both strategies to compare 
their efficiency and indicate which is more effective in relation to this research. 
Transfecting and expressing the final samples into mammalian cells would provide an 
insight into whether these unintended mutations affect the transport activity of the 
68 
 
proteins. It could also highlight the potential molecular recognition sites, areas for 
substrate binding and regions involved with PKC and PKA regulatory pathways 
(Pantavos et al., 2014). 
Similar studies could include domain swapping of the hSVCT proteins and sub cloning 
of those hybrids into expression vectors to evaluate the molecular mechanisms of the 
two transporters. This could provide a better understanding of the transport systems and 
aid the design, development and modifications to pharmaceuticals. It could also provide 
detailed knowledge on how both transporters individually react to interactions with 
current and new substances entering the human body. Ultimately this research on the 
vitamin C transporters could benefit pharmacogenomics, pharmacology and human 
health. 
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Appendix V - hSVCT1 and hSVCT2 Deduced Amino Acid 
Sequences 
 
hSVCT1 
Nucleotide sequence (1897 nucleotides): 
 
CGCCCGGGCAGGTCCTTTGTCAAGTCATCCCCTCTTCTCCTCAGGAACTGCTCAAACCTGTGCCCCAAAG 
ATGAGGGCCCAGGAGGACCTCGAGGGCCGGACACAGCATGAAACCACCAGGGACCCCTCGACCCCGCTAC 
CCACAGAGCCTAAGTTTGACATGTTGTACAAGATCGAGGACGTGCCACCTTGGTACCTGTGCATCCTGCT 
GGGCTTCCAGCACTACCTGACATGCTTCAGTGGTACCATCGCCGTGCCCTTCCTGCTGGCTGAGGCGCTG 
TGTGTGGGCCACGACCAGCACATGGTTAGTCAGCTCATCGGCACCATCTTCACGTGCGTGGGCATCACCA 
CTCTCATCCAGACCACCGTGGGCATCCGGCTGCCGCTGTTCCAGGCCAGTGCCTTTGCATTTCTGGTTCC 
AGCCAAAGCCATACTGGCTCTGGAGAGATGGAAATGCCCCCCGGAAGAGGAGATCTACGGTAACTGGAGT 
CTGCCCCTGAACACCTCTCATATTTGGCACCCACGGATACGGGAGGTCCAGGGTGCAATCATGGTGTCCA 
GCGTGGTGGAGGTGGTGATTGGCCTGCTGGGGCTGCCTGGGGCCCTGCTCAACTACATTGGGCCTCTCAC 
AGTCACCCCCACTGTCTCCCTCATTGGCCTTTCTGTCTTCCAAGCTGCTGGCGACCGAGCTGGCTCCCAC 
TGGGGCATCTCAGCTTGCTCCATTCTCCTGATCATCCTCTTCTCCCAGTACCTGCGCAACCTCACCTTCC 
TGCTGCCTGTCTACCGCTGGGGCAAGGGCCTCACTCTCCTCCGCATCCAGATCTTCAAAATGTTTCCTAT 
CATGCTGGCCATCATGACCGTGTGGCTGCTCTGCTATGTCCTGACCTTGACAGACGTGCTGCCCACAGAC 
CCAAAAGCCTATGGCTTCCAGGCACGAACCGATGCCCGTGGTGACATCATGGCTATTGCACCCTGGATCC 
GCATCCCCTACCCCTGTCAGTGGGGCCTGCCCACGGTGACTGCGGCTGCTGTCCTGGGAATGTTCAGCGC 
CACTCTGGCAGGCATCATTGAGTCCATCGGAGATTACTACGCCTGTGCCCGCCTGGCTGGTGCACCACCC 
CCTCCAGTACATGCTATCAACAGGGGCATCTTCACCGAAGGCATTTGCTGCATCATCGCGGGGCTATTGG 
GCACGGGCAACGGGTCCACCTCGTCCAGTCCCAACATTGGCGTCCTGGGAATTACCAAGGTGGGCAGCCG 
GCGCGTGGTGCAGTATGGTGCGGCTATCATGCTGGTCCTGGGCACCATCGGCAAGTTCACGGCCCTCTTC 
GCCTCGCTCCCTGACCCCATCCTGGGGGGCATGTTCTGCACTCTCTTTGGCATGATTACAGCTGTGGGGC 
TGTCCAACCTGCAATTTGTGGACATGAACTCCTCTCGCAACCTCTTCGTGCTGGGATTTTCCATGTTCTT 
CGGGCTCACGCTGCCCAATTACCTGGAGTCCAACCCTGGCGCCATCAATACAGGCATTCTTGAAGTGGAT 
CAGATTCTGATTGTGCTGCTGACCACGGAGATGTTTGTGGGCGGGTGCCTTGCTTTCATACTTGACAACA 
CAGTGCCAGGGAGCCCAGAGGAGCGTGGTCTGATACAGTGGAAAGCTGGGGCTCATGCCAACAGTGACAT 
GTCTTCCAGCCTCAAGAGCTACGATTTCCCCATTGGGATGGGCATAGTAAAAAGAATTACCTTTCTGAAA 
TACATTCCTATCTGCCCAGTCTTCAAAGGATTTTCTTCAAGTTCAAAAGATCAGATTGCAATTCCAGAAG 
ACACTCCAGAAAATACAGAAACTGCATCTGTGTGCACCAAGGTCTAA 
 
Translation: 
MRAQEDLEGRTQHETTRDPSTPLPTEPKFDMLYKIEDVPPWYLCILLGFQHYLTCFSGT
IAVPFLLAEALCVGHDQHMVSQLIGTIFTCVGITTLIQTTVGIRLPLFQASAFAFLVPA
KAILALERWKCPPEEEIYGNWSLPLNTSHIWHPRIREVQGAIMVSSVVEVVIGLLGLPG
ALLNYIGPLTVTPTVSLIGLSVFQAAGDRAGSHWGISACSILLIILFSQYLRNLTFLLP
VYRWGKGLTLLRIQIFKMFPIMLAIMTVWLLCYVLTLTDVLPTDPKAYGFQARTDARGD
IMAIAPWIRIPYPCQWGLPTVTAAAVLGMFSATLAGIIESIGDYYACARLAGAPPPPVH
AINRGIFTEGICCIIAGLLGTGNGSTSSSPNIGVLGITKVGSRRVVQYGAAIMLVLGTI
GKFTALFASLPDPILGGMFCTLFGMITAVGLSNLQFVDMNSSRNLFVLGFSMFFGLTLP
NYLESNPGAINTGILEVDQILIVLLTTEMFVGGCLAFILDNTVPGSPEERGLIQWKAGA
HANSDMSSSLKSYDFPIGMGIVKRITFLKYIPICPVFKGFSSSSKDQIAIPEDTPENTE
TASVCTKV 
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hSVCT2 
Nucleotide sequence (1953 nucleotides): 
ATGATGGGTATTGGTAAGAATACCACATCCAAATCAATGGAGGCTGGAAGTTCAACAGAAGGCAAATACG 
AAGACGAGGCAAAGCACCCAGCTTTCTTCACTCTTCCGGTGGTGATAAATGGAGGCGCCACCTCCAGCGG 
TGAGCAGGACAATGAGGACACTGAGCTCATGGCGATCTACACTACGGAAAACGGCATTGCAGAAAAGAGC 
TCTCTCGCTGAGACCCTGGATAGCACTGGCAGTCTGGACCCCCAGCGATCAGACATGATTTATACCATAG 
AAGATGTTCCTCCCTGGTACCTGTGTATATTTCTGGGGCTACAGCACTACCTGACATGCTTCAGCGGCAC 
GATCGCAGTGCCCTTCCTGTTGGCCGATGCCATGTGTGTGGGGTACGACCAGTGGGCCACCAGCCAGCTC 
ATTGGGACCATTTTCTTCTGTGTGGGAATCACTACTTTGCTACAGACAACGTTTGGATGCAGGTTACCCC 
TGTTTCAGGCCAGTGCTTTTGCATTTTTGGCCCCTGCTCGAGCCATCCTGTCTTTAGATAAATGGAAATG 
TAACACCACAGATGTTTCAGTTGCCAATGGAACAGCAGAGCTGTTGCACACAGAACACATCTGGTATCCC 
CGGATCCGAGAGATCCAGGGGGCCATCATCATGTCCTCACTGATAGAAGTAGTCATCGGCCTCCTCGGCC 
TGCCTGGGGCTCTACTGAAGTACATCGGTCCCTTGACCATTACACCCACGGTGGCCCTAATTGGCCTCTC 
TGGTTTCCAGGCAGCGGGGGAGAGAGCCGGGAAGCACTGGGGCATTGCCATGCTGACAATATTCCTAGTA 
TTACTGTTTTCTCAATACGCCAGAAATGTTAAATTTCCTCTCCCGATTTATAAATCCAAGAAAGGATGGA 
CTGCGTACAAGTTACAGCTGTTCAAAATGTTCCCTATCATCCTGGCCATCCTGGTATCCTGGCTGCTCTG 
CTTCATCTTCACGGTGACAGACGTCTTCCCTCCCGACAGCACAAAGTATGGCTTCTATGCTCGCACAGAT 
GCCAGGCAAGGCGTGCTTCTGGTAGCCCCGTGGTTTAAGGTTCCATACCCATTTCAGTGGGGACTGCCCA 
CCGTGTCTGCGGCCGGTGTCATCGGCATGCTCAGTGCCGTGGTCGCCAGCATCATCGAGTCTATTGGTGA 
CTACTACGCCTGTGCACGGCTGTCCTGTGCCCCACCCCCCCCCATCCACGCAATAAACAGGGGAATTTTC 
GTGGAAGGCCTCTCCTGTGTTCTTGATGGCATATTTGGTACTGGGAATGGCTCTACTTCATCCAGTCCCA 
ACATTGGAGTTTTGGGAATTACAAAGGTCGGCAGCCGCCGCGTGATACAGTGCGGAGCAGCCCTCATGCT 
CGCTCTGGGCATGATCGGGAAGTTCAGCGCCCTCTTTGCGTCCCTTCCGGATCCTGTGCTGGGAGCCCTG 
TTCTGCACGCTCTTTGGAATGATCACAGCTGTTGGCCTCTCTAACCTGCAGTTCATTGATTTAAATTCTT 
CCCGGAACCTCTTTGTGCTTGGATTTTCGATCTTCTTTGGGCTCGTCCTTCCAAGTTACCTCAGACAGAA 
CCCTCTGGTCACAGGGATAACAGGAATCGATCAAGTGTTGAACGTCCTTCTCACAACTGCTATGTTTGTA 
GGGGGCTGTGTGGCTTTTATCCTGGATAACACCATCCCAGGCACTCCAGAGGAAAGAGGAATCCGGAAAT 
GGAAGAAGGGTGTGGGCAAAGGGAACAAATCACTCGACGGCATGGAGTCGTACAATTTGCCATTTGGCAT 
GAACATTATAAAAAAATACAGATGCTTCAGCTACTTACCCATCAGCCCAACCTTTGTGGGCTACACATGG 
AAAGGCCTCAGGAAGAGCGACAACAGCCGGAGTTCAGATGAAGACTCCCAGGCCACGGGATAG 
 
Translation: 
 
MMGIGKNTTSKSMEAGSSTEGKYEDEAKHPAFFTLPVVINGGATSSGEQDNEDTELMAI
YTTENGIAEKSSLAETLDSTGSLDPQRSDMIYTIEDVPPWYLCIFLGLQHYLTCFSGTI
AVPFLLADAMCVGYDQWATSQLIGTIFFCVGITTLLQTTFGCRLPLFQASAFAFLAPAR
AILSLDKWKCNTTDVSVANGTAELLHTEHIWYPRIREIQGAIIMSSLIEVVIGLLGLPG
ALLKYIGPLTITPTVALIGLSGFQAAGERAGKHWGIAMLTIFLVLLFSQYARNVKFPLP
IYKSKKGWTAYKLQLFKMFPIILAILVSWLLCFIFTVTDVFPPDSTKYGFYARTDARQG
VLLVAPWFKVPYPFQWGLPTVSAAGVIGMLSAVVASIIESIGDYYACARLSCAPPPPIH
AINRGIFVEGLSCVLDGIFGTGNGSTSSSPNIGVLGITKVGSRRVIQCGAALMLALGMI
GKFSALFASLPDPVLGALFCTLFGMITAVGLSNLQFIDLNSSRNLFVLGFSIFFGLVLP
SYLRQNPLVTGITGIDQVLNVLLTTAMFVGGCVAFILDNTIPGTPEERGIRKWKKGVGK
GNKSLDGMESYNLPFGMNIIKKYRCFSYLPISPTFVGYTWKGLRKSDNSRSSDEDSQAT
G 
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Appendix VI- Initial Primer Design for hSVCT1 and hSVCT2 
hsvct1 
ctcaggaactgctcaaacctgtgccccaaagatgagggcccaagaggacctcgagggccgg 
  S  G  T  A  Q  T  C  A  P  K  M  R  A  Q  E  D  L  E  G  R  
gcacagcatgaaaccaccagggacccctcgaccccgctacccacagagcctaagtttgac 
 A  Q  H  E  T  T  R  D  P  S  T  P  L  P  T  E  P  K  F  D  
atgttgtacaagatcgaggacgtgccaccttggtacctgtgcatcctgctgggcttccag 
 M  L  Y  K  I  E  D  V  P  P  W  Y  L  C  I  L  L  G  F  Q  
cactacctgacatgcttcagtggtaccatcgccgtgcccttcctgctggctgaggcgctg 
 H  Y  L  T  C  F  S  G  T  I  A  V  P  F  L  L  A  E  A  L  
tgtgtgggccacgaccagcacatggttagtcagctcatcggcaccatcttcacgtgcgtg 
 C  V  G  H  D  Q  H  M  V  S  Q  L  I  G  T  I  F  T  C  V  
ggcatcaccactctcatccagaccaccgtgggcatccggctgccgctgttccaggccagt 
 G  I  T  T  L  I  Q  T  T  V  G  I  R  L  P  L  F  Q  A  S  
gcctttgcatttctggttccagccaaagccatactggctctggagagatggaaatgcccc 
 A  F  A  F  L  V  P  A  K  A  I  L  A  L  E  R  W  K  C  P  
ccggaagaggagatctacggtaactggagtctgcccctgaacacctctcatatttggcac 
 P  E  E  E  I  Y  G  N  W  S  L  P  L  N  T  S  H  I  W  H  
ccacggatacgggaggtccagggtgcaatcatggtgtccagcgtggtggaggtggtgatt 
 P  R  I  R  E  V  Q  G  A  I  M  V  S  S  V  V  E  V  V  I  
ggcctgctggggctgcctggggccctgctcaactacattgggcctctcacagtcaccccc 
 G  L  L  G  L  P  G  A  L  L  N  Y  I  G  P  L  T  V  T  P  
actgtctccctcattggcctttctgtcttccaagctgctggcgaccgagctggctcccac 
 T  V  S  L  I  G  L  S  V  F  Q  A  A  G  D  R  A  G  S  H  
tggggcatctcagcttgctccattctcctgatcatcctcttctcccagtacctgcgcaac 
 W  G  I  S  A  C  S  I  L  L  I  I  L  F  S  Q  Y  L  R  N  
ctcaccttcctgctgcctgtctaccgctggggcaagggcctcactctcctccgcatccag 
 L  T  F  L  L  P  V  Y  R  W  G  K  G  L  T  L  L  R  I  Q  
atcttcaaaatgtttcctatcatgctggccatcatgaccgtgtggctgctctgctatgtc 
 I  F  K  M  F  P  I  M  L  A  I  M  T  V  W  L  L  C  Y  V  
ctgaccttgacagacgtgctgcccacagacccaaaagcctatggcttccaggcacgaacc 
 L  T  L  T  D  V  L  P  T  D  P  K  A  Y  G  F  Q  A  R  T  
gatgcccgtggtgacatcatggctattgcaccctggatccgcatcccctacccctgtcag 
 D  A  R  G  D  I  M  A  I  A  P  W  I  R  I  P  Y  P  C  Q  
tggggcctgcccacggtgactgcggctgctgtcctgggaatgttcagcgccactctggca 
 W  G  L  P  T  V  T  A  A  A  V  L  G  M  F  S  A  T  L  A  
ggcatcattgagtccatcggagattactacgcctgtgcccgcctggctggtgcaccaccc 
 G  I  I  E  S  I  G  D  Y  Y  A  C  A  R  L  A  G  A  P  P  
cctccagtacatgctatcaacaggggcatcttcaccgaaggcatttgctgcatcatcgcg 
 P  P  V  H  A  I  N  R  G  I  F  T  E  G  I  C  C  I  I  A  
gggctattgggcacgggcaacgggtccacctcgtccagtcccaacattggcgtcctggga 
 G  L  L  G  T  G  N  G  S  T  S  S  S  P  N  I  G  V  L  G  
attaccaaggtgggcagccggcgcgtggtgcagtatggtgcggctatcatgctggtcctg 
 I  T  K  V  G  S  R  R  V  V  Q  Y  G  A  A  I  M  L  V  L S 
ggcaccatcggcaagttcacggccctcttcgcctcgctccctgaccccatcctggggggc 
 G  T  I  G  K  F  T  A  L  F  A  S  L  P  D  P  I  L  G  G  
atgttctgcactctctttggcatgattacagctgtggggctgtccaacctgcaatttgtg 
 M  F  C  T  L  F  G  M  I  T  A  V  G  L  S  N  L  Q  F  V  
gacatgaactcctctcgcaacctcttcgtgctgggattttccatgttcttcgggctcacg 
 D  M  N  S  S  R  N  L  F  V  L  G  F  S  M  F  F  G  L  T  
ctgcccaattacctggagtccaaccctggcgccatcaatacaggcattcttgaagtggat 
 L  P  N  Y  L  E  S  N  P  G  A  I  N  T  G  I  L  E  V  D  
cagattctgattgtgctgctgaccacggagatgtttgtgggcgggtgccttgctttcata 
 Q  I  L  I  V  L  L  T  T  E  M  F  V  G  G  C  L  A  F  I  
cttgacaacacagtgccagggagcccagaggagcgtggtctgatacagtggaaagctggg 
 L  D  N  T  V  P  G  S  P  E  E  R  G  L  I  Q  W  K  A  G  
gctcatgccaacagtgacatgtcttccagcctcaagagctacgatttccccattgggatg 
 A  H  A  N  S  D  M  S  S  S  L  K  S  Y  D  F  P  I  G  M  
ggcatagtaaaaagaattacctttctgaaatacattcctatctgcccagtcttcaaagga 
 G  I  V  K  R  I  T  F  L  K  Y  I  P  I  C  P  V  F  K  G  
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ttttcttcaagttcaaaagatcagattgcaattccagaagacactccagaaaatacagaa 
 F  S  S  S  S  K  D  Q  I  A  I  P  E  D  T  P  E  N  T  E  
actgcatctgtgtgcaccaaggtctgaaaaatgacttccaggaaaggaagcatggtatat 
 T  A  S  V  C  T  K  V  -  K  M  T  S  R  K  G  S  M  V  Y  
aacaggaaaagaaaactacatggggaaccagaagacctaagcctgaaatcccagccctgc 
 N  R  K  R  K  L  H  G  E  P  E  D  L  S  L  K  S  Q  P  C  
ccctaactaacttctgtgtaaactcagataagtcacctttctctgggattcaaatttttg 
 P  -  L  T  S  V  -  T  Q  I  S  H  L  S  L  G  F  K  F  L  
catcagttaaaaaaaaaggggtgggggggaatgggccaaagtctgagtcttagagacttg 
 H  Q  L  K  K  K  G  W  G  G  M  G  Q  S  L  S  L  R  D  L  
taccaatgttatgctatgtctctaaatctttactctcctaagtagacttgtcagcatcta 
 Y  Q  C  Y  A  M  S  L  N  L  Y  S  P  K  -  T  C  Q  H  L  
ggaagaacagctagaaattttcctctgtgatattttagactgcaagttgaaaaaaaaaaa 
 G  R  T  A  R  N  F  P  L  -  Y  F  R  L  Q  V  E  K  K  K  
aaaaaaaaa 
 K  K  K   
 
1) Annealing Temperature = 71.3- 5= 66.3°C 
Forward Primer= VtC1P190SF 
5’-GTCACCCCCACTGTCTCC-3’ 
Reverse Primer= VtC1P190SR 
5’- GGAGACAGTGGGGGTGAC -3’ 
Change Proline (CCC) to Serine (TCC) 
2) Annealing Temperature = 71.3-5=66.3°C 
Forward Primer= VtC1V62GF 
5’-ACCATCGCCGTGCCCTTC-3’ 
Reverse Primer= VtC1V62GR 
5’-GAAGGGCACGGCGATGGT-3’ 
Change Valine (GTG) to Glycine (GGG) 
3) Annealing Temperature = 70.3-5=65.3°C 
Forward Primer = VtC1I96LF 
5’-ACCACTCTCATCCAGACCAC-3’ 
Reverse Primer= VtC1I96LR 
5’-GTGGTCTGGATGAGAGTGGT-3’ 
Change Isoleucine (ATC) to Leucine (CTC) 
4)Annealing Temperature= 71.3-5=66.3°C 
Forward Primer = VtC1L277FF 
5’-ACAGACGTGCTGCCCACAG-3’ 
Reverse Primer= VtC1L277FR 
5’- CTGTGGGCAGCACGTCTGT -3’ 
5) Annealing Temperature= 69.7-5=64.7°C 
Forward Primer= VtC1N385SF 
5’-GTCCAGTCCCAACATTGGC-3’ 
Reverse Primer= VtC1N385SR 
5’-GCCAATGTTGGGACTGGAC-3’ 
Change Asparagine (AAC) to Serine (AGC) 
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>hSVCT2  
 
atgatgggtattggtaagaataccacatccaaatcaatggaggctggaagttcaacagaa 
 M  M  G  I  G  K  N  T  T  S  K  S  M  E  A  G  S  S  T  E  
ggcaaatacgaagacgaggcaaagcacccagctttcttcactcttccggtggtgataaat 
 G  K  Y  E  D  E  A  K  H  P  A  F  F  T  L  P  V  V  I  N  
ggaggcgccacctccagcggtgagcaggacaatgaggacactgagctcatggcgatctac 
 G  G  A  T  S  S  G  E  Q  D  N  E  D  T  E  L  M  A  I  Y  
actacggaaaacggcattgcagaaaagagctctctcgctgagaccctggatagcactggc 
 T  T  E  N  G  I  A  E  K  S  S  L  A  E  T  L  D  S  T  G  
agtctggacccccagcgatcagacatgatttataccatagaagatgttcctccctggtac 
 S  L  D  P  Q  R  S  D  M  I  Y  T  I  E  D  V  P  P  W  Y  
ctgtgtatatttctggggctacagcactacctgacatgcttcagcggcacgatcgcagtg 
 L  C  I  F  L  G  L  Q  H  Y  L  T  C  F  S  G  T  I  A  V  
cccttcctgttggccgatgccatgtgtgtggggtacgaccagtgggccaccagccagctc 
 P  F  L  L  A  D  A  M  C  V  G  Y  D  Q  W  A  T  S  Q  L  
attgggaccattttcttctgtgtgggaatcactactttgctacagacaacgtttggatgc 
 I  G  T  I  F  F  C  V  G  I  T  T  L  L  Q  T  T  F  G  C  
aggttacccctgtttcaggccagtgcttttgcatttttggcccctgctcgagccatcctg 
 R  L  P  L  F  Q  A  S  A  F  A  F  L  A  P  A  R  A  I  L  
tctttagataaatggaaatgtaacaccacagatgtttcagttgccaatggaacagcagag 
 S  L  D  K  W  K  C  N  T  T  D  V  S  V  A  N  G  T  A  E  
ctgttgcacacagaacacatctggtatccccggatccgagagatccagggggccatcatc 
 L  L  H  T  E  H  I  W  Y  P  R  I  R  E  I  Q  G  A  I  I  
atgtcctcactgatagaagtagtcatcggcctcctcggcctgcctggggctctactgaag 
 M  S  S  L  I  E  V  V  I  G  L  L  G  L  P  G  A  L  L  K  
tacatcggtcccttgaccattacacccacggtggccctaattggcctctctggtttccag 
 Y  I  G  P  L  T  I  T  P  T  V  A  L  I  G  L  S  G  F  Q  
gcagcgggggagagagccgggaagcactggggcattgccatgctgacaatattcctagta 
 A  A  G  E  R  A  G  K  H  W  G  I  A  M  L  T  I  F  L  V  
ttactgttttctcaatacgccagaaatgttaaatttcctctcccgatttataaatccaag 
 L  L  F  S  Q  Y  A  R  N  V  K  F  P  L  P  I  Y  K  S  K  
aaaggatggactgcgtacaagttacagctgttcaaaatgttccctatcatcctggccatc 
 K  G  W  T  A  Y  K  L  Q  L  F  K  M  F  P  I  I  L  A  I  
ctggtatcctggctgctctgcttcatcttcacggtgacagacgtcttccctcccgacagc 
 L  V  S  W  L  L  C  F  I  F  T  V  T  D  V  F  P  P  D  S  
acaaagtatggcttctatgctcgcacagatgccaggcaaggcgtgcttctggtagccccg 
 T  K  Y  G  F  Y  A  R  T  D  A  R  Q  G  V  L  L  V  A  P  
tggtttaaggttccatacccatttcagtggggactgcccaccgtgtctgcggccggtgtc 
 W  F  K  V  P  Y  P  F  Q  W  G  L  P  T  V  S  A  A  G  V  
atcggcatgctcagtgccgtggtcgccagcatcatcgagtctattggtgactactacgcc 
 I  G  M  L  S  A  V  V  A  S  I  I  E  S  I  G  D  Y  Y  A  
tgtgcacggctgtcctgtgccccacccccccccatccacgcaataaacaggggaattttc 
 C  A  R  L  S  C  A  P  P  P  P  I  H  A  I  N  R  G  I  F  
gtggaaggcctctcctgtgttcttgatggcatatttggtactgggaatggctctacttca 
 V  E  G  L  S  C  V  L  D  G  I  F  G  T  G  N  G  S  T  S  
tccagtcccaacattggagttttgggaattacaaaggtcggcagccgccgcgtgatacag 
 S  S  P  N  I  G  V  L  G  I  T  K  V  G  S  R  R  V  I  Q  
tgcggagcagccctcatgctcgctctgggcatgatcgggaagttcagcgccctctttgcg 
 C  G  A  A  L  M  L  A  L  G  M  I  G  K  F  S  A  L  F  A  
tcccttccggatcctgtgctgggagccctgttctgcacgctctttggaatgatcacagct 
 S  L  P  D  P  V  L  G  A  L  F  C  T  L  F  G  M  I  T  A  
gttggcctctctaacctgcagttcattgatttaaattcttcccggaacctctttgtgctt 
 V  G  L  S  N  L  Q  F  I  D  L  N  S  S  R  N  L  F  V  L  
ggattttcgatcttctttgggctcgtccttccaagttacctcagacagaaccctctggtc 
 G  F  S  I  F  F  G  L  V  L  P  S  Y  L  R  Q  N  P  L  V  
acagggataacaggaatcgatcaagtgttgaacgtccttctcacaactgctatgtttgta 
 T  G  I  T  G  I  D  Q  V  L  N  V  L  L  T  T  A  M  F  V  
gggggctgtgtggcttttatcctggataacaccatcccaggcactccagaggaaagagga 
 G  G  C  V  A  F  I  L  D  N  T  I  P  G  T  P  E  E  R  G  
atccggaaatggaagaagggtgtgggcaaagggaacaaatcactcgacggcatggagtcg 
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 I  R  K  W  K  K  G  V  G  K  G  N  K  S  L  D  G  M  E  S  
tacaatttgccatttggcatgaacattataaaaaaatacagatgcttcagctacttaccc 
 Y  N  L  P  F  G  M  N  I  I  K  K  Y  R  C  F  S  Y  L  P  
atcagcccaacctttgtgggctacacatggaaaggcctcaggaagagcgacaacagccgg 
 I  S  P  T  F  V  G  Y  T  W  K  G  L  R  K  S  D  N  S  R  
agttcagatgaagactcccaggccacgggatag 
 S  S  D  E  D  S  Q  A  T  G  - 
1)Annealing Temperature =70.3-5=65.3°C 
Forward Primer= VtC2A174VF 
 5’-CATTTTTGGCCCCTGCTCGA-3’ 
Reverse Primer= VtC2A174VR 
5’-TCGAGCAGGGGCCAAAAATG-3’ 
Change Alanine (GCC) to Valine (GTC) 
2) Annealing Temperature = 71.3-5=66.3°C 
Forward Primer= VtC2K184RF 
5’-CCTGTCTTTAGATAAATGGAAATGTAACAC-3’ 
Reverse Primer= VtC2K184RR 
5’-GTGTTACATTTCCATTTATCTAAAGACAGG-3’ 
Change Lysine (AAA) to Arginine (AGA) 
3) Annealing Temperature = 71.3-5=66.3°C 
Forward Primer= VtC2Q353GF 
5’-GATGCCAGGCAAGGCGTG-3’ 
Reverse Primer= VtC2Q353GR 
5’-CACGCCTTGCCTGGCATC-3’ 
Change Glutamine (CAA) to Arginine (CGA) 
4)Annealing Temperature = 71.3-5=66.3°C 
Forward Primer= VtC2D133GF 
5’-GTGGGGTACGACCAGTGG-3’ 
Reverse Primer= VtC2D133GR 
5’- CCACTGGTCGTACCCCAC-3’ 
Change Aspartic Acid (GAC) to Glycine (GGC) 
5) Annealing Temperature =71.3-5=66.3°c 
Forward Primer= VtC2I381LF 
5’-CCGGTGTCATCGGCATGC-3’ 
Reverse Primer= VtC2I381LR 
5’- GCATGCCGATGACACCGG-3’ 
Change Isoleucine (ATC) to Leucine (CTC)(CTC) 
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Appendix VII- Multi Align Images for Varied Species 
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Appendix VIII- Global Alignment of hSVCT1 and hSVCT2 
# Program: needle 
# Rundate: Tue 07 2017 11:32:03 
# Commandline: needle 
#    -asequence emboss_needle-I20160512-133536-0770-85028315-pg.asequence 
#    -bsequence emboss_needle-I20160512-133536-0770-85028315-pg.bsequence 
#    -datafile EDNAFULL 
#    -gapopen 10.0 
#    -gapextend 0.5 
#    -endopen 10.0 
#    -endextend 0.5 
#    -aformat3 pair 
#    -snucleotide1 
#    -snucleotide2 
# Align_format: pair 
# Report_file: stdout 
 Aligned_sequences: 2 
# 1: hsvct1 
# 2: hsvct2 
# Matrix: EDNAFULL 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# Length: 2039 
# Identity:    1236/2039 (60.6%) 
# Similarity:  1236/2039 (60.6%) 
# Gaps:         398/2039 (19.5%) 
# Score: 3695.5 
 
hsvct1             1 --------------------------------------------------      
0 
                                                                        
hsvct2             1 AAGACGAGGCAAAGCACCCAGCTTTCTTCACTCTTCCGGTGGTGATAAAT     
50 
 
hsvct1             1 -------------------ATGAG--GGCCCAGGAGGAC------CTCGA     
23 
                                        .||||  ||.|.|.||||||      ||| | 
hsvct2            51 GGAGGCGCCACCTCCAGCGGTGAGCAGGACAATGAGGACACTGAGCTC-A     
99 
 
hsvct1            24 GGGC-----------CGG-ACACAGCAT----GAAACCACCAGGGACCCC     
57 
                     .|||           ||| |.||.||||    ||||     ||.|..|.| 
hsvct2           100 TGGCGATCTACACTACGGAAAACGGCATTGCAGAAA-----AGAGCTCTC    
144 
 
hsvct1            58 TC-----GACCC-------CGCT----------ACCCACAGAGCCTAAGT     
85 
                     ||     |||||       |.||          ||||.|||.|     .| 
hsvct2           145 TCGCTGAGACCCTGGATAGCACTGGCAGTCTGGACCCCCAGCG-----AT    
189 
 
hsvct1            86 TTGACATGTTGTACAAGATCGAGGACGTGCCACCTTGGTACCTGTGCATC    
135 
                     ..||||||.|.||.|..||.||.||.||.||.||.|||||||||||.||. 
hsvct2           190 CAGACATGATTTATACCATAGAAGATGTTCCTCCCTGGTACCTGTGTATA    
239 
 
hsvct1           136 CTGCTGGGCTTCCAGCACTACCTGACATGCTTCAGTGGTACCATCGCCGT    
185 
                     .|.|||||..|.|||||||||||||||||||||||.||.||.|||||.|| 
hsvct2           240 TTTCTGGGGCTACAGCACTACCTGACATGCTTCAGCGGCACGATCGCAGT    
289 
 
hsvct1           186 GCCCTTCCTGCTGGCTGAGGCGCTGTGTGTGGGCCACGACCAG-----CA    
230 
                     ||||||||||.||||.||.||..||||||||||..||||||||     || 
94 
 
hsvct2           290 GCCCTTCCTGTTGGCCGATGCCATGTGTGTGGGGTACGACCAGTGGGCCA    
339 
 
hsvct1           231 CATGGTTAGTCAGCTCATCGGCACCATCTTCACGTGCGTGGGCATCACCA    
280 
                     |     .||.||||||||.||.|||||.|||...||.|||||.|||||.| 
hsvct2           340 C-----CAGCCAGCTCATTGGGACCATTTTCTTCTGTGTGGGAATCACTA    
384 
 
hsvct1           281 CTCTCATCCAGACCACCGTGGGCAT-CCGGCTGCCGCTGTTCCAGGCCAG    
329 
                     ||.|..|.|||| ||.|||..|.|| |.||.|.||.|||||.|||||||| 
hsvct2           385 CTTTGCTACAGA-CAACGTTTGGATGCAGGTTACCCCTGTTTCAGGCCAG    
433 
 
hsvct1           330 TGCCTTTGCATTTCTGGTTCCAGCCAAAGCCATACTGGCTCTGGAGAGAT    
379 
                     |||.|||||||||.|||..||.||...||||||.|||.||.|.||.|.|| 
hsvct2           434 TGCTTTTGCATTTTTGGCCCCTGCTCGAGCCATCCTGTCTTTAGATAAAT    
483 
 
hsvct1           380 GGAAATG---CCCCCC-------------------GGAAGAGGAGATCTA    
407 
                     |||||||   |.||.|                   ||||.||.|||.||  
hsvct2           484 GGAAATGTAACACCACAGATGTTTCAGTTGCCAATGGAACAGCAGAGCT-    
532 
 
hsvct1           408 CGGTAACTGGAGTCTGC-CCCTGAACACCTCTCATATTTGGCACCCACGG    
456 
                       ||          ||| |.|.||||||       ||.|||.|.||.||| 
hsvct2           533 --GT----------TGCACACAGAACAC-------ATCTGGTATCCCCGG    
563 
 
hsvct1           457 ATACGGGAGGTCCAGGGTGCAATCATGGTGTCCAGCGTGGTGGAGGTGGT    
506 
                     ||.||.|||.|||||||.||.|||||..|||||....||.|.||.||.|| 
hsvct2           564 ATCCGAGAGATCCAGGGGGCCATCATCATGTCCTCACTGATAGAAGTAGT    
613 
 
hsvct1           507 GATTGGCCTGCTGGGGCTGCCTGGGGCCCTGCTCAACTACATTGGGCCTC    
556 
                     .||.|||||.||.||.|||||||||||.||.||.||.|||||.||.||.. 
hsvct2           614 CATCGGCCTCCTCGGCCTGCCTGGGGCTCTACTGAAGTACATCGGTCCCT    
663 
 
hsvct1           557 TCACAGTCACCCCCACTGTCTCCCTCATTGGCCTTTCTGTCTTCCAAGCT    
606 
                     |.||..|.||.|||||.||..||||.||||||||.||||..|||||.||. 
hsvct2           664 TGACCATTACACCCACGGTGGCCCTAATTGGCCTCTCTGGTTTCCAGGCA    
713 
 
hsvct1           607 GCTGGCGACCGAGCTGGCTCCCACTGGGGCATCTCAGCTTGCT--CCATT    
654 
                     ||.||.||..||||.||....|||||||||||..|  |.||||  |.||. 
hsvct2           714 GCGGGGGAGAGAGCCGGGAAGCACTGGGGCATTGC--CATGCTGACAATA    
761 
 
hsvct1           655 CTCCTGATCATCCTCTTCTCCCAGTACCTGC--GCAA-CCTCACCTTCCT    
701 
                     .||||..|..|.||.||.||.||.|||  ||  |.|| ..|.|..||||| 
hsvct2           762 TTCCTAGTATTACTGTTTTCTCAATAC--GCCAGAAATGTTAAATTTCCT    
809 
 
hsvct1           702 GCTGCCTGTCTA-----CC-------GCTGGGGCAAGGGCCTCACTCTCC    
739 
                      ||.||..|.||     ||       |.|||                 .| 
hsvct2           810 -CTCCCGATTTATAAATCCAAGAAAGGATGG-----------------AC    
841 
95 
 
 
hsvct1           740 TCCGCA-----TCCAGATCTTCAAAATGTTTCCTATCATGCTGGCCATCA    
784 
                     |.||.|     |.|||.|.|||||||||||.||||||||.|||||||||. 
hsvct2           842 TGCGTACAAGTTACAGCTGTTCAAAATGTTCCCTATCATCCTGGCCATCC    
891 
 
hsvct1           785 TGACCGT---GTGGCTGCTCTGCTATGTCCTGACCTTGACAGACGTGCTG    
831 
                     ||   ||   .|||||||||||||...||.|.||..|||||||||| ||. 
hsvct2           892 TG---GTATCCTGGCTGCTCTGCTTCATCTTCACGGTGACAGACGT-CTT    
937 
 
hsvct1           832 CCC-----ACAGACCCA-AAAGCCTATGGCTTCCAGGCACGAACCGATGC    
875 
                     |||     ||||   || ||||  |||||||||.|.||.||.||.||||| 
hsvct2           938 CCCTCCCGACAG---CACAAAG--TATGGCTTCTATGCTCGCACAGATGC    
982 
 
hsvct1           876 C--------CGTGGTGACATCATGGCTATTGCACCCTGGATCCGCATCCC    
917 
                     |        ||||    |.|| |||   |.||.||.|||.|.....|.|| 
hsvct2           983 CAGGCAAGGCGTG----CTTC-TGG---TAGCCCCGTGGTTTAAGGTTCC   
1024 
 
hsvct1           918 CTACCCCTGTCAGTGGGGCCTGCCCACGGTGACTGCGGCTGCTGTCCTGG    
967 
                     .|||||.|.|||||||||.||||||||.|||.|||||||.|.||||.|.| 
hsvct2          1025 ATACCCATTTCAGTGGGGACTGCCCACCGTGTCTGCGGCCGGTGTCATCG   
1074 
 
hsvct1           968 GAATGTTCAGCGCCACTCTGG----CAGGCATCATTGAGTCCATCGGAGA   
1013 
                     |.|||.||||.|||   .|||    || |||||||.|||||.||.||.|| 
hsvct2          1075 GCATGCTCAGTGCC---GTGGTCGCCA-GCATCATCGAGTCTATTGGTGA   
1120 
 
hsvct1          1014 TTACTACGCCTGTGCCCGCCTGGCTGGTGCACCACCCCCTCCAGTACATG   
1063 
                     .||||||||||||||.||.|||.|..||||.||||||||.||..|.||.| 
hsvct2          1121 CTACTACGCCTGTGCACGGCTGTCCTGTGCCCCACCCCCCCCCATCCACG   
1170 
 
hsvct1          1064 CTATCAACAGGGGCATCTTCACCGAAGGCATTTGCTG----CATCATCGC   
1109 
                     |.||.||||||||.||.|||...||||||.|.|.|||    |.|.||    
hsvct2          1171 CAATAAACAGGGGAATTTTCGTGGAAGGCCTCTCCTGTGTTCTTGAT---   
1217 
 
hsvct1          1110 GGGGC-TATTGGGCACGGGCAACGGGTCCACCTCGTCCAGTCCCAACATT   
1158 
                       ||| ||||.||.||.||.||.||.||.||.||.||||||||||||||| 
hsvct2          1218 --GGCATATTTGGTACTGGGAATGGCTCTACTTCATCCAGTCCCAACATT   
1265 
 
hsvct1          1159 GGCGTCCTGGGAATTACCAAGGTGGGCAGCCGGCGCGTGGTGCAGTATGG   
1208 
                     ||.||..||||||||||.|||||.||||||||.||||||.|.||||..|| 
hsvct2          1266 GGAGTTTTGGGAATTACAAAGGTCGGCAGCCGCCGCGTGATACAGTGCGG   
1315 
 
hsvct1          1209 TGCGGCTATCATGCTGGTCCTGGGCACCATCGGCAAGTTCACGGCCCTCT   
1258 
                     .||.||..|||||||.|..|||||||..|||||.|||||||..||||||| 
hsvct2          1316 AGCAGCCCTCATGCTCGCTCTGGGCATGATCGGGAAGTTCAGCGCCCTCT   
1365 
 
96 
 
hsvct1          1259 TCGCCTCGCTCCCTGACCCCATCCTGGGGGGCATGTTCTGCACTCTCTTT   
1308 
                     |.||.||.||.||.||.||..|.|||||.|.|.||||||||||.|||||| 
hsvct2          1366 TTGCGTCCCTTCCGGATCCTGTGCTGGGAGCCCTGTTCTGCACGCTCTTT   
1415 
 
hsvct1          1309 GGCATGATTACAGCTGTGGGGCTGTCCAACCTGCAATTTGTGGACATGAA   
1358 
                     ||.|||||.||||||||.||.||.||.||||||||.||..|.||..|.|| 
hsvct2          1416 GGAATGATCACAGCTGTTGGCCTCTCTAACCTGCAGTTCATTGATTTAAA   
1465 
 
hsvct1          1359 CTCCTCTCGCAACCTCTTCGTGCTGGGATTTTCCATGTTCTTCGGGCTCA   
1408 
                     .||.||.||.||||||||.|||||.||||||||.||.|||||.||||||. 
hsvct2          1466 TTCTTCCCGGAACCTCTTTGTGCTTGGATTTTCGATCTTCTTTGGGCTCG   
1515 
 
hsvct1          1409 CGCTGCCCAATTACCTGGAGTC-CAACC--CTGGCGCCATCAATACAGGC   
1455 
                     ..||.||.|.|||||| .||.| .||||  ||||     ||   |||||. 
hsvct2          1516 TCCTTCCAAGTTACCT-CAGACAGAACCCTCTGG-----TC---ACAGGG   
1556 
 
hsvct1          1456 AT-TCTTGAAGTGGATCAGATTCTGATTGTGCTGCTGACCACGGAGATGT   
1504 
                     || .|..||| |.|||||..|..|||..||.||.||.||.||.|..|||| 
hsvct2          1557 ATAACAGGAA-TCGATCAAGTGTTGAACGTCCTTCTCACAACTGCTATGT   
1605 
 
hsvct1          1505 TTGTGGGCGGGTGCCTTGCTTTCATACTTGACAACACAGTGCCAGGGAGC   
1554 
                     ||||.||.||.||..|.|||||.||.||.||.|||||..|.|||||.|.. 
hsvct2          1606 TTGTAGGGGGCTGTGTGGCTTTTATCCTGGATAACACCATCCCAGGCACT   
1655 
 
hsvct1          1555 CCAGAGGAGCGTGGTCTGATACAGTGGAAAGCTGG-----GGCTCATGCC   
1599 
                     ||||||||..|.||   .||.|   |||||  |||     ||.|...|.| 
hsvct2          1656 CCAGAGGAAAGAGG---AATCC---GGAAA--TGGAAGAAGGGTGTGGGC   
1697 
 
hsvct1          1600 AACAGTG-ACATGTC-TTC--CAGCCTCAAGAGCTACGATTTCCCCATTG   
1645 
                     || ||.| |||..|| .||  |.||.|..||...|||.||||.||..||| 
hsvct2          1698 AA-AGGGAACAAATCACTCGACGGCATGGAGTCGTACAATTTGCCATTTG   
1746 
 
hsvct1          1646 GGATGGGCATAGTAAAAAGAATTAC-----CTTTCTGAAATACATTCCTA   
1690 
                     |.|||..|||  ||.|||.||.|||     ||   |.|..|||.|.||.| 
hsvct2          1747 GCATGAACAT--TATAAAAAAATACAGATGCT---TCAGCTACTTACCCA   
1791 
 
hsvct1          1691 TCTGCCCAGTCTT---------------CAAAGGATTTTCTTCAAGTTCA   
1725 
                     ||.|||||..|||               .|||||     |.|||.|     
hsvct2          1792 TCAGCCCAACCTTTGTGGGCTACACATGGAAAGG-----CCTCAGG----   
1832 
 
hsvct1          1726 AAAGA-----------------TCAGATTGCAATTCCAGAAGACACTCCA   
1758 
                      ||||                 ||||||          ||||||.| ||| 
hsvct2          1833 -AAGAGCGACAACAGCCGGAGTTCAGAT----------GAAGACTC-CCA   
1870 
 
hsvct1          1759 GAAAATACAGAAACTGCATCTGTGTGCACCAAGGTCTAA   1797 
                     |        |..||.|.||            ||       
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Appendix IX- Local Alignment of hSVCT1 and hSVCT2 
Query: ./wwwtmp/lalign26697.1.seq 
  1>>>hsvct1 598 bp - 598 aa 
Library: ./wwwtmp/lalign266551.2.seq 
      650 residues in     1 sequences 
 
Statistics: (shuffled [500]) MLE statistics: Lambda= 0.1594;  K=0.01575 
 statistics sampled from 1 (1) to 500 sequences 
Threshold: E() < 10 score: 40 
Algorithm: Smith-Waterman (SSE2, Michael Farrar 2006) (7.2 Nov 2010) 
Parameters: BL50 matrix (15:-5), open/ext: -12/-2 
 Scan time:  0.040 
 
>>hsvct2 650 bp                                           (650 aa) 
 Waterman-Eggert score: 2636;  612.2 bits; E(1) <  2e-179 
68.3% identity (88.5% similar) in 546 aa overlap (28-572:86-629) 
 
        30        40        50        60        70        80        
hsvct1 KFDMLYKIEDVPPWYLCILLGFQHYLTCFSGTIAVPFLLAEALCVGHDQHMVSQLIGTIF 
       . ::.: :::::::::::.::.::::::::::::::::::.:.:::.::  .:::::::: 
hsvct2 RSDMIYTIEDVPPWYLCIFLGLQHYLTCFSGTIAVPFLLADAMCVGYDQWATSQLIGTIF 
          90       100       110       120       130       140      
 
        90       100       110       120       130       140        
hsvct1 TCVGITTLIQTTVGIRLPLFQASAFAFLVPAKAILALERWKCPPEEEIYGNWSLPL-NTS 
        :::::::.::: : :::::::::::::.::.:::.:..:::   .   .: .  : .:  
hsvct2 FCVGITTLLQTTFGCRLPLFQASAFAFLAPARAILSLDKWKCNTTDVSVANGTAELLHTE 
         150       160       170       180       190       200      
 
        150       160       170       180       190       200       
hsvct1 HIWHPRIREVQGAIMVSSVVEVVIGLLGLPGALLNYIGPLTVTPTVSLIGLSVFQAAGDR 
       :::.:::::.::::..::..::::::::::::::.::::::.::::.::::: :::::.: 
hsvct2 HIWYPRIREIQGAIIMSSLIEVVIGLLGLPGALLKYIGPLTITPTVALIGLSGFQAAGER 
         210       220       230       240       250       260      
 
        210       220       230       240       250       260       
hsvct1 AGSHWGISACSILLIILFSQYLRNLTFLLPVYRWGKGLTLLRIQIFKMFPIMLAIMTVWL 
       ::.::::.  .:.:..::::: ::. : ::.:.  :: :  ..:.::::::.:::.. :: 
hsvct2 AGKHWGIAMLTIFLVLLFSQYARNVKFPLPIYKSKKGWTAYKLQLFKMFPIILAILVSWL 
         270       280       290       300       310       320      
 
        270       280       290       300       310       320       
hsvct1 LCYVLTLTDVLPTDPKAYGFQARTDARGDIMAIAPWIRIPYPCQWGLPTVTAAAVLGMFS 
       ::...:.:::.: :   ::: ::::::  .. .:::...::: :::::::.::.:.::.: 
hsvct2 LCFIFTVTDVFPPDSTKYGFYARTDARQGVLLVAPWFKVPYPFQWGLPTVSAAGVIGMLS 
         330       340       350       360       370       380      
 
        330       340       350       360       370       380       
hsvct1 ATLAGIIESIGDYYACARLAGAPPPPVHAINRGIFTEGICCIIAGLLGTGNGSTSSSPNI 
       :..:.::::::::::::::. :::::.::::::::.::. :.. :..::::::::::::: 
hsvct2 AVVASIIESIGDYYACARLSCAPPPPIHAINRGIFVEGLSCVLDGIFGTGNGSTSSSPNI 
         390       400       410       420       430       440      
 
        390       400       410       420       430       440       
hsvct1 GVLGITKVGSRRVVQYGAAIMLVLGTIGKFTALFASLPDPILGGMFCTLFGMITAVGLSN 
       :::::::::::::.: :::.::.:: ::::.:::::::::.::..::::::::::::::: 
hsvct2 GVLGITKVGSRRVIQCGAALMLALGMIGKFSALFASLPDPVLGALFCTLFGMITAVGLSN 
         450       460       470       480       490       500      
 
        450       460       470       480       490       500       
hsvct1 LQFVDMNSSRNLFVLGFSMFFGLTLPNYLESNPGAINTGILEVDQILIVLLTTEMFVGGC 
       :::.:.::::::::::::.::::.::.::..::  . :::  .::.: ::::: :::::: 
hsvct2 LQFIDLNSSRNLFVLGFSIFFGLVLPSYLRQNP--LVTGITGIDQVLNVLLTTAMFVGGC 
         510       520       530         540       550       560    
 
        510       520       530       540       550       560       
98 
 
hsvct1 LAFILDNTVPGSPEERGLIQWKAGAHANSDMSSSLKSYDFPIGMGIVKRITFLKYIPICP 
       .:::::::.::.:::::. .:: :.  ..   ....::..:.::.:.:.   ..:.:: : 
hsvct2 VAFILDNTIPGTPEERGIRKWKKGVGKGNKSLDGMESYNLPFGMNIIKKYRCFSYLPISP 
           570       580       590       600       610       620    
 
        570   
hsvct1 VFKGFS 
       .: :.. 
hsvct2 TFVGYT 
              
>-- 
 Waterman-Eggert score: 66;  21.2 bits; E(1) <  0.15 
17.8% identity (55.0% similar) in 129 aa overlap (159-287:458-582) 
 
      160       170       180       190       200       210         
hsvct1 AIMVSSVVEVVIGLLGLPGALLNYIGPLTVTPTVSLIGLSVFQAAGDRAGSHWGISACSI 
       .:. .... ...:..:  .::.  . :  :  ..    .... :.:    .   ...    
hsvct2 VIQCGAALMLALGMIGKFSALFASL-PDPVLGALFCTLFGMITAVGLSNLQFIDLNSSRN 
       460       470       480        490       500       510       
 
      220       230       240       250       260       270         
hsvct1 LLIILFSQYLRNLTFLLPVYRWGKGLTLLRIQIFKMFPIMLAIMTVWLLCYVLTLTDVLP 
       :... :: .   . ..:: :   . :.     : ... ..:.       : .. : ...: 
hsvct2 LFVLGFSIF---FGLVLPSYLRQNPLVTGITGIDQVLNVLLTTAMFVGGCVAFILDNTIP 
        520          530       540       550       560       570    
 
      280        
hsvct1 TDPKAYGFQ 
         :.  :.. 
hsvct2 GTPEERGIR 
           580   
>-- 
 Waterman-Eggert score: 64;  20.7 bits; E(1) <  0.2 
20.3% identity (58.0% similar) in 69 aa overlap (351-410:210-278) 
 
              360       370             380       390          400  
hsvct1 PPVHAINRGIFTEGICCIIAGLLGTGN------GSTSSSPNIGVLGIT---KVGSRRVVQ 
       : .. :. .:.  ..  .. ::::  .      :  . .:.....:..    .: :   . 
hsvct2 PRIREIQGAIIMSSLIEVVIGLLGLPGALLKYIGPLTITPTVALIGLSGFQAAGERAGKH 
     210       220       230       240       250       260          
 
             410 
hsvct1 YGAAIMLVL 
       .: :.. .. 
hsvct2 WGIAMLTIF 
     270         
598 residues in 1 query   sequences 
650 residues in 1 library sequences 
 Scomplib [36.3.5e Nov, 2012(preload8)] 
 start: Tue Feb 07 15:45:31 2017 done: Tue Feb 07 15:45:32 2017 
 Total Scan time:  0.040 Total Display time:  0.040 
 
Function used was LALIGN [36.3.5e Nov, 2012(preload8)] 
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Appendix X- GIBCO-BRL Oligonucleotide Tm Table 
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Appendix XI- 1kb Ladder (Promega; Catalogue No. G5711) 
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Appendix XII- Research Notebook Copies 
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